Tag Archives: Neuralink

Portable and non-invasive (?) mind-reading AI (artificial intelligence) turns thoughts into text and some thoughts about the near future

First, here’s some of the latest research and if by ‘non-invasive,’ you mean that electrodes are not being planted in your brain, then this December 12, 2023 University of Technology Sydney (UTS) press release (also on EurekAlert) highlights non-invasive mind-reading AI via a brain-computer interface (BCI), Note: Links have been removed,

In a world-first, researchers from the GrapheneX-UTS Human-centric Artificial Intelligence Centre at the University of Technology Sydney (UTS) have developed a portable, non-invasive system that can decode silent thoughts and turn them into text. 

The technology could aid communication for people who are unable to speak due to illness or injury, including stroke or paralysis. It could also enable seamless communication between humans and machines, such as the operation of a bionic arm or robot.

The study has been selected as the spotlight paper at the NeurIPS conference, a top-tier annual meeting that showcases world-leading research on artificial intelligence and machine learning, held in New Orleans on 12 December 2023.

The research was led by Distinguished Professor CT Lin, Director of the GrapheneX-UTS HAI Centre, together with first author Yiqun Duan and fellow PhD candidate Jinzhou Zhou from the UTS Faculty of Engineering and IT.

In the study participants silently read passages of text while wearing a cap that recorded electrical brain activity through their scalp using an electroencephalogram (EEG). A demonstration of the technology can be seen in this video [See UTS press release].

The EEG wave is segmented into distinct units that capture specific characteristics and patterns from the human brain. This is done by an AI model called DeWave developed by the researchers. DeWave translates EEG signals into words and sentences by learning from large quantities of EEG data. 

“This research represents a pioneering effort in translating raw EEG waves directly into language, marking a significant breakthrough in the field,” said Distinguished Professor Lin.

“It is the first to incorporate discrete encoding techniques in the brain-to-text translation process, introducing an innovative approach to neural decoding. The integration with large language models is also opening new frontiers in neuroscience and AI,” he said.

Previous technology to translate brain signals to language has either required surgery to implant electrodes in the brain, such as Elon Musk’s Neuralink [emphasis mine], or scanning in an MRI machine, which is large, expensive, and difficult to use in daily life.

These methods also struggle to transform brain signals into word level segments without additional aids such as eye-tracking, which restrict the practical application of these systems. The new technology is able to be used either with or without eye-tracking.

The UTS research was carried out with 29 participants. This means it is likely to be more robust and adaptable than previous decoding technology that has only been tested on one or two individuals, because EEG waves differ between individuals. 

The use of EEG signals received through a cap, rather than from electrodes implanted in the brain, means that the signal is noisier. In terms of EEG translation however, the study reported state-of the art performance, surpassing previous benchmarks.

“The model is more adept at matching verbs than nouns. However, when it comes to nouns, we saw a tendency towards synonymous pairs rather than precise translations, such as ‘the man’ instead of ‘the author’,” said Duan. [emphases mine; synonymous, eh? what about ‘woman’ or ‘child’ instead of the ‘man’?]

“We think this is because when the brain processes these words, semantically similar words might produce similar brain wave patterns. Despite the challenges, our model yields meaningful results, aligning keywords and forming similar sentence structures,” he said.

The translation accuracy score is currently around 40% on BLEU-1. The BLEU score is a number between zero and one that measures the similarity of the machine-translated text to a set of high-quality reference translations. The researchers hope to see this improve to a level that is comparable to traditional language translation or speech recognition programs, which is closer to 90%.

The research follows on from previous brain-computer interface technology developed by UTS in association with the Australian Defence Force [ADF] that uses brainwaves to command a quadruped robot, which is demonstrated in this ADF video [See my June 13, 2023 posting, “Mind-controlled robots based on graphene: an Australian research story” for the story and embedded video].

About one month after the research announcement regarding the University of Technology Sydney’s ‘non-invasive’ brain-computer interface (BCI), I stumbled across an in-depth piece about the field of ‘non-invasive’ mind-reading research.

Neurotechnology and neurorights

Fletcher Reveley’s January 18, 2024 article on salon.com (originally published January 3, 2024 on Undark) shows how quickly the field is developing and raises concerns, Note: Links have been removed,

One afternoon in May 2020, Jerry Tang, a Ph.D. student in computer science at the University of Texas at Austin, sat staring at a cryptic string of words scrawled across his computer screen:

“I am not finished yet to start my career at twenty without having gotten my license I never have to pull out and run back to my parents to take me home.”

The sentence was jumbled and agrammatical. But to Tang, it represented a remarkable feat: A computer pulling a thought, however disjointed, from a person’s mind.

For weeks, ever since the pandemic had shuttered his university and forced his lab work online, Tang had been at home tweaking a semantic decoder — a brain-computer interface, or BCI, that generates text from brain scans. Prior to the university’s closure, study participants had been providing data to train the decoder for months, listening to hours of storytelling podcasts while a functional magnetic resonance imaging (fMRI) machine logged their brain responses. Then, the participants had listened to a new story — one that had not been used to train the algorithm — and those fMRI scans were fed into the decoder, which used GPT1, a predecessor to the ubiquitous AI chatbot ChatGPT, to spit out a text prediction of what it thought the participant had heard. For this snippet, Tang compared it to the original story:

“Although I’m twenty-three years old I don’t have my driver’s license yet and I just jumped out right when I needed to and she says well why don’t you come back to my house and I’ll give you a ride.”

The decoder was not only capturing the gist of the original, but also producing exact matches of specific words — twenty, license. When Tang shared the results with his adviser, a UT Austin neuroscientist named Alexander Huth who had been working towards building such a decoder for nearly a decade, Huth was floored. “Holy shit,” Huth recalled saying. “This is actually working.” By the fall of 2021, the scientists were testing the device with no external stimuli at all — participants simply imagined a story and the decoder spat out a recognizable, albeit somewhat hazy, description of it. “What both of those experiments kind of point to,” said Huth, “is the fact that what we’re able to read out here was really like the thoughts, like the idea.”

The scientists brimmed with excitement over the potentially life-altering medical applications of such a device — restoring communication to people with locked-in syndrome, for instance, whose near full-body paralysis made talking impossible. But just as the potential benefits of the decoder snapped into focus, so too did the thorny ethical questions posed by its use. Huth himself had been one of the three primary test subjects in the experiments, and the privacy implications of the device now seemed visceral: “Oh my god,” he recalled thinking. “We can look inside my brain.”

Huth’s reaction mirrored a longstanding concern in neuroscience and beyond: that machines might someday read people’s minds. And as BCI technology advances at a dizzying clip, that possibility and others like it — that computers of the future could alter human identities, for example, or hinder free will — have begun to seem less remote. “The loss of mental privacy, this is a fight we have to fight today,” said Rafael Yuste, a Columbia University neuroscientist. “That could be irreversible. If we lose our mental privacy, what else is there to lose? That’s it, we lose the essence of who we are.”

Spurred by these concerns, Yuste and several colleagues have launched an international movement advocating for “neurorights” — a set of five principles Yuste argues should be enshrined in law as a bulwark against potential misuse and abuse of neurotechnology. But he may be running out of time.

Reveley’s January 18, 2024 article provides fascinating context and is well worth reading if you have the time.

For my purposes, I’m focusing on ethics, Note: Links have been removed,

… as these and other advances propelled the field forward, and as his own research revealed the discomfiting vulnerability of the brain to external manipulation, Yuste found himself increasingly concerned by the scarce attention being paid to the ethics of these technologies. Even Obama’s multi-billion-dollar BRAIN Initiative, a government program designed to advance brain research, which Yuste had helped launch in 2013 and supported heartily, seemed to mostly ignore the ethical and societal consequences of the research it funded. “There was zero effort on the ethical side,” Yuste recalled.

Yuste was appointed to the rotating advisory group of the BRAIN Initiative in 2015, where he began to voice his concerns. That fall, he joined an informal working group to consider the issue. “We started to meet, and it became very evident to me that the situation was a complete disaster,” Yuste said. “There was no guidelines, no work done.” Yuste said he tried to get the group to generate a set of ethical guidelines for novel BCI technologies, but the effort soon became bogged down in bureaucracy. Frustrated, he stepped down from the committee and, together with a University of Washington bioethicist named Sara Goering, decided to independently pursue the issue. “Our aim here is not to contribute to or feed fear for doomsday scenarios,” the pair wrote in a 2016 article in Cell, “but to ensure that we are reflective and intentional as we prepare ourselves for the neurotechnological future.”

In the fall of 2017, Yuste and Goering called a meeting at the Morningside Campus of Columbia, inviting nearly 30 experts from all over the world in such fields as neurotechnology, artificial intelligence, medical ethics, and the law. By then, several other countries had launched their own versions of the BRAIN Initiative, and representatives from Australia, Canada [emphasis mine], China, Europe, Israel, South Korea, and Japan joined the Morningside gathering, along with veteran neuroethicists and prominent researchers. “We holed ourselves up for three days to study the ethical and societal consequences of neurotechnology,” Yuste said. “And we came to the conclusion that this is a human rights issue. These methods are going to be so powerful, that enable to access and manipulate mental activity, and they have to be regulated from the angle of human rights. That’s when we coined the term ‘neurorights.’”

The Morningside group, as it became known, identified four principal ethical priorities, which were later expanded by Yuste into five clearly defined neurorights: The right to mental privacy, which would ensure that brain data would be kept private and its use, sale, and commercial transfer would be strictly regulated; the right to personal identity, which would set boundaries on technologies that could disrupt one’s sense of self; the right to fair access to mental augmentation, which would ensure equality of access to mental enhancement neurotechnologies; the right of protection from bias in the development of neurotechnology algorithms; and the right to free will, which would protect an individual’s agency from manipulation by external neurotechnologies. The group published their findings in an often-cited paper in Nature.

But while Yuste and the others were focused on the ethical implications of these emerging technologies, the technologies themselves continued to barrel ahead at a feverish speed. In 2014, the first kick of the World Cup was made by a paraplegic man using a mind-controlled robotic exoskeleton. In 2016, a man fist bumped Obama using a robotic arm that allowed him to “feel” the gesture. The following year, scientists showed that electrical stimulation of the hippocampus could improve memory, paving the way for cognitive augmentation technologies. The military, long interested in BCI technologies, built a system that allowed operators to pilot three drones simultaneously, partially with their minds. Meanwhile, a confusing maelstrom of science, science-fiction, hype, innovation, and speculation swept the private sector. By 2020, over $33 billion had been invested in hundreds of neurotech companies — about seven times what the NIH [US National Institutes of Health] had envisioned for the 12-year span of the BRAIN Initiative itself.

Now back to Tang and Huth (from Reveley’s January 18, 2024 article), Note: Links have been removed,

Central to the ethical questions Huth and Tang grappled with was the fact that their decoder, unlike other language decoders developed around the same time, was non-invasive — it didn’t require its users to undergo surgery. Because of that, their technology was free from the strict regulatory oversight that governs the medical domain. (Yuste, for his part, said he believes non-invasive BCIs pose a far greater ethical challenge than invasive systems: “The non-invasive, the commercial, that’s where the battle is going to get fought.”) Huth and Tang’s decoder faced other hurdles to widespread use — namely that fMRI machines are enormous, expensive, and stationary. But perhaps, the researchers thought, there was a way to overcome that hurdle too.

The information measured by fMRI machines — blood oxygenation levels, which indicate where blood is flowing in the brain — can also be measured with another technology, functional Near-Infrared Spectroscopy, or fNIRS. Although lower resolution than fMRI, several expensive, research-grade, wearable fNIRS headsets do approach the resolution required to work with Huth and Tang’s decoder. In fact, the scientists were able to test whether their decoder would work with such devices by simply blurring their fMRI data to simulate the resolution of research-grade fNIRS. The decoded result “doesn’t get that much worse,” Huth said.

And while such research-grade devices are currently cost-prohibitive for the average consumer, more rudimentary fNIRS headsets have already hit the market. Although these devices provide far lower resolution than would be required for Huth and Tang’s decoder to work effectively, the technology is continually improving, and Huth believes it is likely that an affordable, wearable fNIRS device will someday provide high enough resolution to be used with the decoder. In fact, he is currently teaming up with scientists at Washington University to research the development of such a device.

Even comparatively primitive BCI headsets can raise pointed ethical questions when released to the public. Devices that rely on electroencephalography, or EEG, a commonplace method of measuring brain activity by detecting electrical signals, have now become widely available — and in some cases have raised alarm. In 2019, a school in Jinhua, China, drew criticism after trialing EEG headbands that monitored the concentration levels of its pupils. (The students were encouraged to compete to see who concentrated most effectively, and reports were sent to their parents.) Similarly, in 2018 the South China Morning Post reported that dozens of factories and businesses had begun using “brain surveillance devices” to monitor workers’ emotions, in the hopes of increasing productivity and improving safety. The devices “caused some discomfort and resistance in the beginning,” Jin Jia, then a brain scientist at Ningbo University, told the reporter. “After a while, they got used to the device.”

But the primary problem with even low-resolution devices is that scientists are only just beginning to understand how information is actually encoded in brain data. In the future, powerful new decoding algorithms could discover that even raw, low-resolution EEG data contains a wealth of information about a person’s mental state at the time of collection. Consequently, nobody can definitively know what they are giving away when they allow companies to collect information from their brains.

Huth and Tang concluded that brain data, therefore, should be closely guarded, especially in the realm of consumer products. In an article on Medium from last April, Tang wrote that “decoding technology is continually improving, and the information that could be decoded from a brain scan a year from now may be very different from what can be decoded today. It is crucial that companies are transparent about what they intend to do with brain data and take measures to ensure that brain data is carefully protected.” (Yuste said the Neurorights Foundation recently surveyed the user agreements of 30 neurotech companies and found that all of them claim ownership of users’ brain data — and most assert the right to sell that data to third parties. [emphases mine]) Despite these concerns, however, Huth and Tang maintained that the potential benefits of these technologies outweighed their risks, provided the proper guardrails [emphasis mine] were put in place.

It would seem the first guardrails are being set up in South America (from Reveley’s January 18, 2024 article), Note: Links have been removed,

On a hot summer night in 2019, Yuste sat in the courtyard of an adobe hotel in the north of Chile with his close friend, the prominent Chilean doctor and then-senator Guido Girardi, observing the vast, luminous skies of the Atacama Desert and discussing, as they often did, the world of tomorrow. Girardi, who every year organizes the Congreso Futuro, Latin America’s preeminent science and technology event, had long been intrigued by the accelerating advance of technology and its paradigm-shifting impact on society — “living in the world at the speed of light,” as he called it. Yuste had been a frequent speaker at the conference, and the two men shared a conviction that scientists were birthing technologies powerful enough to disrupt the very notion of what it meant to be human.

Around midnight, as Yuste finished his pisco sour, Girardi made an intriguing proposal: What if they worked together to pass an amendment to Chile’s constitution, one that would enshrine protections for mental privacy as an inviolable right of every Chilean? It was an ambitious idea, but Girardi had experience moving bold pieces of legislation through the senate; years earlier he had spearheaded Chile’s famous Food Labeling and Advertising Law, which required companies to affix health warning labels on junk food. (The law has since inspired dozens of countries to pursue similar legislation.) With BCI, here was another chance to be a trailblazer. “I said to Rafael, ‘Well, why don’t we create the first neuro data protection law?’” Girardi recalled. Yuste readily agreed.

… Girardi led the political push, promoting a piece of legislation that would amend Chile’s constitution to protect mental privacy. The effort found surprising purchase across the political spectrum, a remarkable feat in a country famous for its political polarization. In 2021, Chile’s congress unanimously passed the constitutional amendment, which Piñera [Sebastián Piñera] swiftly signed into law. (A second piece of legislation, which would establish a regulatory framework for neurotechnology, is currently under consideration by Chile’s congress.) “There was no divide between the left or right,” recalled Girardi. “This was maybe the only law in Chile that was approved by unanimous vote.” Chile, then, had become the first country in the world to enshrine “neurorights” in its legal code.

Even before the passage of the Chilean constitutional amendment, Yuste had begun meeting regularly with Jared Genser, an international human rights lawyer who had represented such high-profile clients as Desmond Tutu, Liu Xiaobo, and Aung San Suu Kyi. (The New York Times Magazine once referred to Genser as “the extractor” for his work with political prisoners.) Yuste was seeking guidance on how to develop an international legal framework to protect neurorights, and Genser, though he had just a cursory knowledge of neurotechnology, was immediately captivated by the topic. “It’s fair to say he blew my mind in the first hour of discussion,” recalled Genser. Soon thereafter, Yuste, Genser, and a private-sector entrepreneur named Jamie Daves launched the Neurorights Foundation, a nonprofit whose first goal, according to its website, is “to protect the human rights of all people from the potential misuse or abuse of neurotechnology.”

To accomplish this, the organization has sought to engage all levels of society, from the United Nations and regional governing bodies like the Organization of American States, down to national governments, the tech industry, scientists, and the public at large. Such a wide-ranging approach, said Genser, “is perhaps insanity on our part, or grandiosity. But nonetheless, you know, it’s definitely the Wild West as it comes to talking about these issues globally, because so few people know about where things are, where they’re heading, and what is necessary.”

This general lack of knowledge about neurotech, in all strata of society, has largely placed Yuste in the role of global educator — he has met several times with U.N. Secretary-General António Guterres, for example, to discuss the potential dangers of emerging neurotech. And these efforts are starting to yield results. Guterres’s 2021 report, “Our Common Agenda,” which sets forth goals for future international cooperation, urges “updating or clarifying our application of human rights frameworks and standards to address frontier issues,” such as “neuro-technology.” Genser attributes the inclusion of this language in the report to Yuste’s advocacy efforts.

But updating international human rights law is difficult, and even within the Neurorights Foundation there are differences of opinion regarding the most effective approach. For Yuste, the ideal solution would be the creation of a new international agency, akin to the International Atomic Energy Agency — but for neurorights. “My dream would be to have an international convention about neurotechnology, just like we had one about atomic energy and about certain things, with its own treaty,” he said. “And maybe an agency that would essentially supervise the world’s efforts in neurotechnology.”

Genser, however, believes that a new treaty is unnecessary, and that neurorights can be codified most effectively by extending interpretation of existing international human rights law to include them. The International Covenant of Civil and Political Rights, for example, already ensures the general right to privacy, and an updated interpretation of the law could conceivably clarify that that clause extends to mental privacy as well.

There is no need for immediate panic (from Reveley’s January 18, 2024 article),

… while Yuste and the others continue to grapple with the complexities of international and national law, Huth and Tang have found that, for their decoder at least, the greatest privacy guardrails come not from external institutions but rather from something much closer to home — the human mind itself. Following the initial success of their decoder, as the pair read widely about the ethical implications of such a technology, they began to think of ways to assess the boundaries of the decoder’s capabilities. “We wanted to test a couple kind of principles of mental privacy,” said Huth. Simply put, they wanted to know if the decoder could be resisted.

In late 2021, the scientists began to run new experiments. First, they were curious if an algorithm trained on one person could be used on another. They found that it could not — the decoder’s efficacy depended on many hours of individualized training. Next, they tested whether the decoder could be thrown off simply by refusing to cooperate with it. Instead of focusing on the story that was playing through their headphones while inside the fMRI machine, participants were asked to complete other mental tasks, such as naming random animals, or telling a different story in their head. “Both of those rendered it completely unusable,” Huth said. “We didn’t decode the story they were listening to, and we couldn’t decode anything about what they were thinking either.”

Given how quickly this field of research is progressing, it seems like a good idea to increase efforts to establish neurorights (from Reveley’s January 18, 2024 article),

For Yuste, however, technologies like Huth and Tang’s decoder may only mark the beginning of a mind-boggling new chapter in human history, one in which the line between human brains and computers will be radically redrawn — or erased completely. A future is conceivable, he said, where humans and computers fuse permanently, leading to the emergence of technologically augmented cyborgs. “When this tsunami hits us I would say it’s not likely it’s for sure that humans will end up transforming themselves — ourselves — into maybe a hybrid species,” Yuste said. He is now focused on preparing for this future.

In the last several years, Yuste has traveled to multiple countries, meeting with a wide assortment of politicians, supreme court justices, U.N. committee members, and heads of state. And his advocacy is beginning to yield results. In August, Mexico began considering a constitutional reform that would establish the right to mental privacy. Brazil is currently considering a similar proposal, while Spain, Argentina, and Uruguay have also expressed interest, as has the European Union. In September [2023], neurorights were officially incorporated into Mexico’s digital rights charter, while in Chile, a landmark Supreme Court ruling found that Emotiv Inc, a company that makes a wearable EEG headset, violated Chile’s newly minted mental privacy law. That suit was brought by Yuste’s friend and collaborator, Guido Girardi.

“This is something that we should take seriously,” he [Huth] said. “Because even if it’s rudimentary right now, where is that going to be in five years? What was possible five years ago? What’s possible now? Where’s it gonna be in five years? Where’s it gonna be in 10 years? I think the range of reasonable possibilities includes things that are — I don’t want to say like scary enough — but like dystopian enough that I think it’s certainly a time for us to think about this.”

You can find The Neurorights Foundation here and/or read Reveley’s January 18, 2024 article on salon.com or as originally published January 3, 2024 on Undark. Finally, thank you for the article, Fletcher Reveley!

Neural (brain) implants and hype (long read)

There was a big splash a few weeks ago when it was announced that Neuralink’s (Elon Musk company) brain implant had been surgically inserted into its first human patient.

Getting approval

David Tuffley, senior lecturer in Applied Ethics & CyberSecurity at Griffith University (Australia), provides a good overview of the road Neuralink took to getting FDA (US Food and Drug Administration) approval for human clinical trials in his May 29, 2023 essay for The Conversation, Note: Links have been removed,

Since its founding in 2016, Elon Musk’s neurotechnology company Neuralink has had the ambitious mission to build a next-generation brain implant with at least 100 times more brain connections than devices currently approved by the US Food and Drug Administration (FDA).

The company has now reached a significant milestone, having received FDA approval to begin human trials. So what were the issues keeping the technology in the pre-clinical trial phase for as long as it was? And have these concerns been addressed?

Neuralink is making a Class III medical device known as a brain-computer interface (BCI). The device connects the brain to an external computer via a Bluetooth signal, enabling continuous communication back and forth.

The device itself is a coin-sized unit called a Link. It’s implanted within a small disk-shaped cutout in the skull using a precision surgical robot. The robot splices a thousand tiny threads from the Link to certain neurons in the brain. [emphasis mine] Each thread is about a quarter the diameter of a human hair.

The company says the device could enable precise control of prosthetic limbs, giving amputees natural motor skills. It could revolutionise treatment for conditions such as Parkinson’s disease, epilepsy and spinal cord injuries. It also shows some promise for potential treatment of obesity, autism, depression, schizophrenia and tinnitus.

Several other neurotechnology companies and researchers have already developed BCI technologies that have helped people with limited mobility regain movement and complete daily tasks.

In February 2021, Musk said Neuralink was working with the FDA to secure permission to start initial human trials later that year. But human trials didn’t commence in 2021.

Then, in March 2022, Neuralink made a further application to the FDA to establish its readiness to begin humans trials.

One year and three months later, on May 25 2023, Neuralink finally received FDA approval for its first human clinical trial. Given how hard Neuralink has pushed for permission to begin, we can assume it will begin very soon. [emphasis mine]

The approval has come less than six months after the US Office of the Inspector General launched an investigation into Neuralink over potential animal welfare violations. [emphasis mine]

In accessible language, Tuffley goes on to discuss the FDA’s specific technical issues with implants and how they were addressed in his May 29, 2023 essay.

More about how Neuralink’s implant works and some concerns

Canadian Broadcasting Corporation (CBC) journalist Andrew Chang offers an almost 13 minute video, “Neuralink brain chip’s first human patient. How does it work?” Chang is a little overenthused for my taste but he offers some good information about neural implants, along with informative graphics in his presentation.

So, Tuffley was right about Neuralink getting ready quickly for human clinical trials as you can guess from the title of Chang’s CBC video.

Jennifer Korn announced that recruitment had started in her September 20, 2023 article for CNN (Cable News Network), Note: Links have been removed,

Elon Musk’s controversial biotechnology startup Neuralink opened up recruitment for its first human clinical trial Tuesday, according to a company blog.

After receiving approval from an independent review board, Neuralink is set to begin offering brain implants to paralysis patients as part of the PRIME Study, the company said. PRIME, short for Precise Robotically Implanted Brain-Computer Interface, is being carried out to evaluate both the safety and functionality of the implant.

Trial patients will have a chip surgically placed in the part of the brain that controls the intention to move. The chip, installed by a robot, will then record and send brain signals to an app, with the initial goal being “to grant people the ability to control a computer cursor or keyboard using their thoughts alone,” the company wrote.

Those with quadriplegia [sometimes known as tetraplegia] due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS) may qualify for the six-year-long study – 18 months of at-home and clinic visits followed by follow-up visits over five years. Interested people can sign up in the patient registry on Neuralink’s website.

Musk has been working on Neuralink’s goal of using implants to connect the human brain to a computer for five years, but the company so far has only tested on animals. The company also faced scrutiny after a monkey died in project testing in 2022 as part of efforts to get the animal to play Pong, one of the first video games.

I mentioned three Reuters investigative journalists who were reporting on Neuralink’s animal abuse allegations (emphasized in Tuffley’s essay) in a July 7, 2023 posting, “Global dialogue on the ethics of neurotechnology on July 13, 2023 led by UNESCO.” Later that year, Neuralink was cleared by the US Department of Agriculture (see September 24,, 2023 article by Mahnoor Jehangir for BNN Breaking).

Plus, Neuralink was being investigated over more allegations according to a February 9, 2023 article by Rachel Levy for Reuters, this time regarding hazardous pathogens,

The U.S. Department of Transportation said on Thursday it is investigating Elon Musk’s brain-implant company Neuralink over the potentially illegal movement of hazardous pathogens.

A Department of Transportation spokesperson told Reuters about the probe after the Physicians Committee of Responsible Medicine (PCRM), an animal-welfare advocacy group,wrote to Secretary of Transportation Pete Buttigieg, opens new tab earlier on Thursday to alert it of records it obtained on the matter.

PCRM said it obtained emails and other documents that suggest unsafe packaging and movement of implants removed from the brains of monkeys. These implants may have carried infectious diseases in violation of federal law, PCRM said.

There’s an update about the hazardous materials in the next section. Spoiler alert, the company got fined.

Neuralink’s first human implant

A January 30, 2024 article (Associated Press with files from Reuters) on the Canadian Broadcasting Corporation’s (CBC) online news webspace heralded the latest about Neurlink’s human clinical trials,

The first human patient received an implant from Elon Musk’s computer-brain interface company Neuralink over the weekend, the billionaire says.

In a post Monday [January 29, 2024] on X, the platform formerly known as Twitter, Musk said that the patient received the implant the day prior and was “recovering well.” He added that “initial results show promising neuron spike detection.”

Spikes are activity by neurons, which the National Institutes of Health describe as cells that use electrical and chemical signals to send information around the brain and to the body.

The billionaire, who owns X and co-founded Neuralink, did not provide additional details about the patient.

When Neuralink announced in September [2023] that it would begin recruiting people, the company said it was searching for individuals with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig’s disease.

Neuralink reposted Musk’s Monday [January 29, 2024] post on X, but did not publish any additional statements acknowledging the human implant. The company did not immediately respond to requests for comment from The Associated Press or Reuters on Tuesday [January 30, 2024].

In a separate Monday [January 29, 2024] post on X, Musk said that the first Neuralink product is called “Telepathy” — which, he said, will enable users to control their phones or computers “just by thinking.” He said initial users would be those who have lost use of their limbs.

The startup’s PRIME Study is a trial for its wireless brain-computer interface to evaluate the safety of the implant and surgical robot.

Now for the hazardous materials, January 30, 2024 article, Note: A link has been removed,

Earlier this month [January 2024], a Reuters investigation found that Neuralink was fined for violating U.S. Department of Transportation (DOT) rules regarding the movement of hazardous materials. During inspections of the company’s facilities in Texas and California in February 2023, DOT investigators found the company had failed to register itself as a transporter of hazardous material.

They also found improper packaging of hazardous waste, including the flammable liquid Xylene. Xylene can cause headaches, dizziness, confusion, loss of muscle co-ordination and even death, according to the U.S. Centers for Disease Control and Prevention.

The records do not say why Neuralink would need to transport hazardous materials or whether any harm resulted from the violations.

Skeptical thoughts about Elon Musk and Neuralink

Earlier this month (February 2024), the British Broadcasting Corporation (BBC) published an article by health reporters, Jim Reed and Joe McFadden, that highlights the history of brain implants, the possibilities, and notes some of Elon Musk’s more outrageous claims for Neuralink’s brain implants,

Elon Musk is no stranger to bold claims – from his plans to colonise Mars to his dreams of building transport links underneath our biggest cities. This week the world’s richest man said his Neuralink division had successfully implanted its first wireless brain chip into a human.

Is he right when he says this technology could – in the long term – save the human race itself?

Sticking electrodes into brain tissue is really nothing new.

In the 1960s and 70s electrical stimulation was used to trigger or suppress aggressive behaviour in cats. By the early 2000s monkeys were being trained to move a cursor around a computer screen using just their thoughts.

“It’s nothing novel, but implantable technology takes a long time to mature, and reach a stage where companies have all the pieces of the puzzle, and can really start to put them together,” says Anne Vanhoestenberghe, professor of active implantable medical devices, at King’s College London.

Neuralink is one of a growing number of companies and university departments attempting to refine and ultimately commercialise this technology. The focus, at least to start with, is on paralysis and the treatment of complex neurological conditions.

Reed and McFadden’s February 2024 BBC article describes a few of the other brain implant efforts, Note: Links have been removed,

One of its [Neuralink’s] main rivals, a start-up called Synchron backed by funding from investment firms controlled by Bill Gates and Jeff Bezos, has already implanted its stent-like device into 10 patients.

Back in December 2021, Philip O’Keefe, a 62-year old Australian who lives with a form of motor neurone disease, composed the first tweet using just his thoughts to control a cursor.

And researchers at Lausanne University in Switzerland have shown it is possible for a paralysed man to walk again by implanting multiple devices to bypass damage caused by a cycling accident.

In a research paper published this year, they demonstrated a signal could be beamed down from a device in his brain to a second device implanted at the base of his spine, which could then trigger his limbs to move.

Some people living with spinal injuries are sceptical about the sudden interest in this new kind of technology.

“These breakthroughs get announced time and time again and don’t seem to be getting any further along,” says Glyn Hayes, who was paralysed in a motorbike accident in 2017, and now runs public affairs for the Spinal Injuries Association.

If I could have anything back, it wouldn’t be the ability to walk. It would be putting more money into a way of removing nerve pain, for example, or ways to improve bowel, bladder and sexual function.” [emphasis mine]

Musk, however, is focused on something far more grand for Neuralink implants, from Reed and McFadden’s February 2024 BBC article, Note: A link has been removed,

But for Elon Musk, “solving” brain and spinal injuries is just the first step for Neuralink.

The longer-term goal is “human/AI symbiosis” [emphasis mine], something he describes as “species-level important”.

Musk himself has already talked about a future where his device could allow people to communicate with a phone or computer “faster than a speed typist or auctioneer”.

In the past, he has even said saving and replaying memories may be possible, although he recognised “this is sounding increasingly like a Black Mirror episode.”

One of the experts quoted in Reed and McFadden’s February 2024 BBC article asks a pointed question,

… “At the moment, I’m struggling to see an application that a consumer would benefit from, where they would take the risk of invasive surgery,” says Prof Vanhoestenberghe.

“You’ve got to ask yourself, would you risk brain surgery just to be able to order a pizza on your phone?”

Rae Hodge’s February 11, 2024 article about Elon Musk and his hyped up Neuralink implant for Salon is worth reading in its entirety but for those who don’t have the time or need a little persuading, here are a few excerpts, Note 1: This is a warning; Hodge provides more detail about the animal cruelty allegations; Note 2: Links have been removed,

Elon Musk’s controversial brain-computer interface (BCI) tech, Neuralink, has supposedly been implanted in its first recipient — and as much as I want to see progress for treatment of paralysis and neurodegenerative disease, I’m not celebrating. I bet the neuroscientists he reportedly drove out of the company aren’t either, especially not after seeing the gruesome torture of test monkeys and apparent cover-up that paved the way for this moment. 

All of which is an ethics horror show on its own. But the timing of Musk’s overhyped implant announcement gives it an additional insulting subtext. Football players are currently in a battle for their lives against concussion-based brain diseases that plague autopsy reports of former NFL players. And Musk’s boast of false hope came just two weeks before living players take the field in the biggest and most brutal game of the year. [2024 Super Bowl LVIII]

ESPN’s Kevin Seifert reports neuro-damage is up this year as “players suffered a total of 52 concussions from the start of training camp to the beginning of the regular season. The combined total of 213 preseason and regular season concussions was 14% higher than 2021 but within range of the three-year average from 2018 to 2020 (203).”

I’m a big fan of body-tech: pacemakers, 3D-printed hips and prosthetic limbs that allow you to wear your wedding ring again after 17 years. Same for brain chips. But BCI is the slow-moving front of body-tech development for good reason. The brain is too understudied. Consequences of the wrong move are dire. Overpromising marketable results on profit-driven timelines — on the backs of such a small community of researchers in a relatively new field — would be either idiotic or fiendish. 

Brown University’s research in the sector goes back to the 1990s. Since the emergence of a floodgate-opening 2002 study and the first implant in 2004 by med-tech company BrainGate, more promising results have inspired broader investment into careful research. But BrainGate’s clinical trials started back in 2009, and as noted by Business Insider’s Hilary Brueck, are expected to continue until 2038 — with only 15 participants who have devices installed. 

Anne Vanhoestenberghe is a professor of active implantable medical devices at King’s College London. In a recent release, she cautioned against the kind of hype peddled by Musk.

“Whilst there are a few other companies already using their devices in humans and the neuroscience community have made remarkable achievements with those devices, the potential benefits are still significantly limited by technology,” she said. “Developing and validating core technology for long term use in humans takes time and we need more investments to ensure we do the work that will underpin the next generation of BCIs.” 

Neuralink is a metal coin in your head that connects to something as flimsy as an app. And we’ve seen how Elon treats those. We’ve also seen corporate goons steal a veteran’s prosthetic legs — and companies turn brain surgeons and dentists into repo-men by having them yank anti-epilepsy chips out of people’s skulls, and dentures out of their mouths. 

“I think we have a chance with Neuralink to restore full-body functionality to someone who has a spinal cord injury,” Musk said at a 2023 tech summit, adding that the chip could possibly “make up for whatever lost capacity somebody has.”

Maybe BCI can. But only in the careful hands of scientists who don’t have Musk squawking “go faster!” over their shoulders. His greedy frustration with the speed of BCI science is telling, as is the animal cruelty it reportedly prompted.

There have been other examples of Musk’s grandiosity. Notably, David Lee expressed skepticism about hyperloop in his August 13, 2013 article for BBC news online

Is Elon Musk’s Hyperloop just a pipe dream?

Much like the pun in the headline, the bright idea of transporting people using some kind of vacuum-like tube is neither new nor imaginative.

There was Robert Goddard, considered the “father of modern rocket propulsion”, who claimed in 1909 that his vacuum system could suck passengers from Boston to New York at 1,200mph.

And then there were Soviet plans for an amphibious monorail  – mooted in 1934  – in which two long pods would start their journey attached to a metal track before flying off the end and slipping into the water like a two-fingered Kit Kat dropped into some tea.

So ever since inventor and entrepreneur Elon Musk hit the world’s media with his plans for the Hyperloop, a healthy dose of scepticism has been in the air.

“This is by no means a new idea,” says Rod Muttram, formerly of Bombardier Transportation and Railtrack.

“It has been previously suggested as a possible transatlantic transport system. The only novel feature I see is the proposal to put the tubes above existing roads.”

Here’s the latest I’ve found on hyperloop, from the Hyperloop Wikipedia entry,

As of 2024, some companies continued to pursue technology development under the hyperloop moniker, however, one of the biggest, well funded players, Hyperloop One, declared bankruptcy and ceased operations in 2023.[15]

Musk is impatient and impulsive as noted in a September 12, 2023 posting by Mike Masnick on Techdirt, Note: A link has been removed,

The Batshit Crazy Story Of The Day Elon Musk Decided To Personally Rip Servers Out Of A Sacramento Data Center

Back on Christmas Eve [December 24, 2022] of last year there were some reports that Elon Musk was in the process of shutting down Twitter’s Sacramento data center. In that article, a number of ex-Twitter employees were quoted about how much work it would be to do that cleanly, noting that there’s a ton of stuff hardcoded in Twitter code referring to that data center (hold that thought).

That same day, Elon tweeted out that he had “disconnected one of the more sensitive server racks.”

Masnick follows with a story of reckless behaviour from someone who should have known better.

Ethics of implants—where to look for more information

While Musk doesn’t use the term when he describes a “human/AI symbiosis” (presumably by way of a neural implant), he’s talking about a cyborg. Here’s a 2018 paper, which looks at some of the implications,

Do you want to be a cyborg? The moderating effect of ethics on neural implant acceptance by Eva Reinares-Lara, Cristina Olarte-Pascual, and Jorge Pelegrín-Borondo. Computers in Human Behavior Volume 85, August 2018, Pages 43-53 DOI: https://doi.org/10.1016/j.chb.2018.03.032

This paper is open access.

Getting back to Neuralink, I have two blog posts that discuss the company and the ethics of brain implants from way back in 2021.

First, there’s Jazzy Benes’ March 1, 2021 posting on the Santa Clara University’s Markkula Center for Applied Ethics blog. It stands out as it includes a discussion of the disabled community’s issues, Note: Links have been removed,

In the heart of Silicon Valley we are constantly enticed by the newest technological advances. With the big influencers Grimes [a Canadian musician and the mother of three children with Elon Musk] and Lil Uzi Vert publicly announcing their willingness to become experimental subjects for Elon Musk’s Neuralink brain implantation device, we are left wondering if future technology will actually give us “the knowledge of the Gods.” Is it part of the natural order for humans to become omniscient beings? Who will have access to the devices? What other ethical considerations must be discussed before releasing such technology to the public?

A significant issue that arises from developing technologies for the disabled community is the assumption that disabled persons desire the abilities of what some abled individuals may define as “normal.” Individuals with disabilities may object to technologies intended to make them fit an able-bodied norm. “Normal” is relative to each individual, and it could be potentially harmful to use a deficit view of disability, which means judging a disability as a deficiency. However, this is not to say that all disabled individuals will reject a technology that may enhance their abilities. Instead, I believe it is a consideration that must be recognized when developing technologies for the disabled community, and it can only be addressed through communication with disabled persons. As a result, I believe this is a conversation that must be had with the community for whom the technology is developed–disabled persons.

With technologies that aim to address disabilities, we walk a fine line between therapeutics and enhancement. Though not the first neural implant medical device, the Link may have been the first BCI system openly discussed for its potential transhumanism uses, such as “enhanced cognitive abilities, memory storage and retrieval, gaming, telepathy, and even symbiosis with machines.” …

Benes also discusses transhumanism, privacy issues, and consent issues. It’s a thoughtful reading experience.

Second is a July 9, 2021 posting by anonymous on the University of California at Berkeley School of Information blog which provides more insight into privacy and other issues associated with data collection (and introduced me to the concept of decisional interference),

As the development of microchips furthers and advances in neuroscience occur, the possibility for seamless brain-machine interfaces, where a device decodes inputs from the user’s brain to perform functions, becomes more of a reality. These various forms of these technologies already exist. However, technological advances have made implantable and portable devices possible. Imagine a future where humans don’t need to talk to each other, but rather can transmit their thoughts directly to another person. This idea is the eventual goal of Elon Musk, the founder of Neuralink. Currently, Neuralink is one of the main companies involved in the advancement of this type of technology. Analysis of the Neuralink’s technology and their overall mission statement provide an interesting insight into the future of this type of human-computer interface and the potential privacy and ethical concerns with this technology.

As this technology further develops, several privacy and ethical concerns come into question. To begin, using Solove’s Taxonomy as a privacy framework, many areas of potential harm are revealed. In the realm of information collection, there is much risk. Brain-computer interfaces, depending on where they are implanted, could have access to people’s most private thoughts and emotions. This information would need to be transmitted to another device for processing. The collection of this information by companies such as advertisers would represent a major breach of privacy. Additionally, there is risk to the user from information processing. These devices must work concurrently with other devices and often wirelessly. Given the widespread importance of cloud computing in much of today’s technology, offloading information from these devices to the cloud would be likely. Having the data stored in a database puts the user at the risk of secondary use if proper privacy policies are not implemented. The trove of information stored within the information collected from the brain is vast. These datasets could be combined with existing databases such as browsing history on Google to provide third parties with unimaginable context on individuals. Lastly, there is risk for information dissemination, more specifically, exposure. The information collected and processed by these devices would need to be stored digitally. Keeping such private information, even if anonymized, would be a huge potential for harm, as the contents of the information may in itself be re-identifiable to a specific individual. Lastly there is risk for invasions such as decisional interference. Brain-machine interfaces would not only be able to read information in the brain but also write information. This would allow the device to make potential emotional changes in its users, which be a major example of decisional interference. …

For the most recent Neuralink and brain implant ethics piece, there’s this February 14, 2024 essay on The Conversation, which, unusually, for this publication was solicited by the editors, Note: Links have been removed,

In January 2024, Musk announced that Neuralink implanted its first chip in a human subject’s brain. The Conversation reached out to two scholars at the University of Washington School of Medicine – Nancy Jecker, a bioethicst, and Andrew Ko, a neurosurgeon who implants brain chip devices – for their thoughts on the ethics of this new horizon in neuroscience.

Information about the implant, however, is scarce, aside from a brochure aimed at recruiting trial subjects. Neuralink did not register at ClinicalTrials.gov, as is customary, and required by some academic journals. [all emphases mine]

Some scientists are troubled by this lack of transparency. Sharing information about clinical trials is important because it helps other investigators learn about areas related to their research and can improve patient care. Academic journals can also be biased toward positive results, preventing researchers from learning from unsuccessful experiments.

Fellows at the Hastings Center, a bioethics think tank, have warned that Musk’s brand of “science by press release, while increasingly common, is not science. [emphases mine]” They advise against relying on someone with a huge financial stake in a research outcome to function as the sole source of information.

When scientific research is funded by government agencies or philanthropic groups, its aim is to promote the public good. Neuralink, on the other hand, embodies a private equity model [emphasis mine], which is becoming more common in science. Firms pooling funds from private investors to back science breakthroughs may strive to do good, but they also strive to maximize profits, which can conflict with patients’ best interests.

In 2022, the U.S. Department of Agriculture investigated animal cruelty at Neuralink, according to a Reuters report, after employees accused the company of rushing tests and botching procedures on test animals in a race for results. The agency’s inspection found no breaches, according to a letter from the USDA secretary to lawmakers, which Reuters reviewed. However, the secretary did note an “adverse surgical event” in 2019 that Neuralink had self-reported.

In a separate incident also reported by Reuters, the Department of Transportation fined Neuralink for violating rules about transporting hazardous materials, including a flammable liquid.

…the possibility that the device could be increasingly shown to be helpful for people with disabilities, but become unavailable due to loss of research funding. For patients whose access to a device is tied to a research study, the prospect of losing access after the study ends can be devastating. [emphasis mine] This raises thorny questions about whether it is ever ethical to provide early access to breakthrough medical interventions prior to their receiving full FDA approval.

Not registering a clinical trial would seem to suggest there won’t be much oversight. As for Musk’s “science by press release” activities, I hope those will be treated with more skepticism by mainstream media although that seems unlikely given the current situation with journalism (more about that in a future post).

As for the issues associated with private equity models for science research and the problem of losing access to devices after a clinical trial is ended, my April 5, 2022 posting, “Going blind when your neural implant company flirts with bankruptcy (long read)” offers some cautionary tales, in addition to being the most comprehensive piece I’ve published on ethics and brain implants.

My July 17, 2023 posting, “Unveiling the Neurotechnology Landscape: Scientific Advancements, Innovations and Major Trends—a UNESCO report” offers a brief overview of the international scene.

Ethical nanobiotechnology

This paper on ethics (aside: I have a few comments after the news release and citation) comes from the US Pacific Northwest National Laboratory (PNNL) according to a July 12, 2023 news item on phys.org,

Prosthetics moved by thoughts. Targeted treatments for aggressive brain cancer. Soldiers with enhanced vision or bionic ears. These powerful technologies sound like science fiction, but they’re becoming possible thanks to nanoparticles.

“In medicine and other biological settings, nanotechnology is amazing and helpful, but it could be harmful if used improperly,” said Pacific Northwest National Laboratory (PNNL) chemist Ashley Bradley, part of a team of researchers who conducted a comprehensive survey of nanobiotechnology applications and policies.

Their research, available in Health Security, works to sum up the very large, active field of nanotechnology in biology applications, draw attention to regulatory gaps, and offer areas for further consideration.

A July 12, 2023 PNNL news release (also on EurekAlert), which originated the news item, delves further into the topic, Note: A link has been removed,

“In our research, we learned there aren’t many global regulations yet,” said Bradley. “And we need to create a common set of rules to figure out the ethical boundaries.”

Nanoparticles, big differences

Nanoparticles are clusters of molecules with different properties than large amounts of the same substances. In medicine and other biology applications, these properties allow nanoparticles to act as the packaging that delivers treatments through cell walls and the difficult to cross blood-brain barrier.

“You can think of the nanoparticles a little bit like the plastic around shredded cheese,” said PNNL chemist Kristin Omberg. “It makes it possible to get something perishable directly where you want it, but afterwards you’ve got to deal with a whole lot of substance where it wasn’t before.”

Unfortunately, dealing with nanoparticles in new places isn’t straightforward. Carbon is pencil lead, nano carbon conducts electricity. The same material may have different properties at the nanoscale, but most countries still regulate it the same as bulk material, if the material is regulated at all.

For example, zinc oxide, a material that was stable and unreactive as a pigment in white paint, is now accumulating in oceans when used as nanoparticles in sunscreen, warranting a call to create alternative reef-safe sunscreens. And although fats and lipids aren’t regulated, the researchers suggest which agencies could weigh in on regulations were fats to become after-treatment byproducts.

The article also inventories national and international agencies, organizations, and governing bodies with an interest in understanding how nanoparticles break down or react in a living organism and the environmental life cycle of a nanoparticle. Because nanobiotechnology spans materials science, biology, medicine, environmental science, and tech, these disparate research and regulatory disciplines must come together, often for the first time—to fully understand the impact on humans and the environment.

Dual use: Good for us, bad for us

Like other quickly growing fields, there’s a time lag between the promise of new advances and the possibilities of unintended uses.

“There were so many more applications than we thought there were,” said Bradley, who collected exciting nanobio examples such as Alzheimer’s treatment, permanent contact lenses, organ replacement, and enhanced muscle recovery, among others.

The article also highlights concerns about crossing the blood-brain barrier, thought-initiated control of computers, and nano-enabled DNA editing where the researchers suggest more caution, questioning, and attention could be warranted. This attention spans everything from deep fundamental research and regulations all the way to what Omberg called “the equivalent of tattoo removal” if home-DNA splicing attempts go south.

The researchers draw parallels to more established fields such as synthetic bio and pharmacology, which offer lessons to be learned from current concerns such as the unintended consequences of fentanyl and opioids. They believe these fields also offer examples of innovative coordination between science and ethics, such as synthetic bio’s IGEM [The International Genetically Engineered Machine competition]—student competition, to think about not just how to create, but also to shape the use and control of new technologies.

Omberg said unusually enthusiastic early reviewers of the article contributed even more potential uses and concerns, demonstrating that experts in many fields recognize ethical nanobiotechnology is an issue to get in front of. “This is a train that’s going. It will be sad if 10 years from now, we haven’t figured how to talk about it.”

Funding for the team’s research was supported by PNNL’s Biorisk Beyond the List National Security Directorate Objective.

Here’s a link to and a citation for the paper,

The Promise of Emergent Nanobiotechnologies for In Vivo Applications and Implications for Safety and Security by Anne M. Arnold, Ashley M. Bradley, Karen L. Taylor, Zachary C. Kennedy, and Kristin M. Omberg. Health Security.Oct 2022.408-423.Published in Volume: 20 Issue 5: October 17, 2022 DOI: https://doi.org/10.1089/hs.2022.0014 Published Online:17 Oct 2022

This paper is open access.

You can find out more about IGEM (The International Genetically Engineered Machine competition) here.

Comments (brief)

It seems a little odd that the news release (“Prosthetics moved by thoughts …”) and the paper both reference neurotechnology without ever mentioning it by name. Here’s the reference from the paper, Note: Links have been removed,

Nanoparticles May Be Developed to Facilitate Cognitive Enhancements

The development and implementation of NPs that enhance cognitive function has yet to be realized. However, recent advances on the micro- and macro-level with neural–machine interfacing provide the building blocks necessary to develop this technology on the nanoscale. A noninvasive brain–computer interface to control a robotic arm was developed by teams at 2 universities.157 A US-based company, Neuralink, [emphasis mine] is at the forefront of implementing implantable, intracortical microelectrodes that provide an interface between the human brain and technology.158,159 Utilization of intracortical microelectrodes may ultimately provide thought-initiated access and control of computers and mobile devices, and possibly expand cognitive function by accessing underutilized areas of the brain.158

Neuralink (founded by Elon Musk) is controversial for its animal testing practices. You can find out more in Björn Ólafsson’s May 30, 2023 article for Sentient Media.

The focus on nanoparticles as the key factor in the various technologies and applications mentioned seems narrow but necessary given the breadth of topics covered in the paper as the authors themselves note in the paper’s abstract,

… In this article, while not comprehensive, we attempt to illustrate the breadth and promise of bionanotechnology developments, and how they may present future safety and security challenges. Specifically, we address current advancements to streamline the development of engineered NPs for in vivo applications and provide discussion on nano–bio interactions, NP in vivo delivery, nanoenhancement of human performance, nanomedicine, and the impacts of NPs on human health and the environment.

They have a good overview of the history and discussions about nanotechnology risks and regulation. It’s international in scope with a heavy emphasis on US efforts, as one would expect.

For anyone who’s interested in the neurotechnology end of things, I’ve got a July 17, 2023 commentary “Unveiling the Neurotechnology Landscape: Scientific Advancements, Innovations and Major Trends—a UNESCO report.” The report was launched July 13, 2023 during UNESCO’s Global dialogue on the ethics of neurotechnology (see my July 7, 2023 posting about the then upcoming dialogue for links to more UNESCO information). Both the July 17 and July 7, 2023 postings included additional information about Neuralink.

Unveiling the Neurotechnology Landscape: Scientific Advancements, Innovations and Major Trends—a UNESCO report

Launched on Thursday, July 13, 2023 during UNESCO’s (United Nations Educational, Scientific, and Cultural Organization) “Global dialogue on the ethics of neurotechnology,” is a report tying together the usual measures of national scientific supremacy (number of papers published and number of patents filed) with information on corporate investment in the field. Consequently, “Unveiling the Neurotechnology Landscape: Scientific Advancements, Innovations and Major Trends” by Daniel S. Hain, Roman Jurowetzki, Mariagrazia Squicciarini, and Lihui Xu provides better insight into the international neurotechnology scene than is sometimes found in these kinds of reports. By the way, the report is open access.

Here’s what I mean, from the report‘s short summary,

Since 2013, government investments in this field have exceeded $6 billion. Private investment has also seen significant growth, with annual funding experiencing a 22-fold increase from 2010 to 2020, reaching $7.3 billion and totaling $33.2 billion.

This investment has translated into a 35-fold growth in neuroscience publications between 2000-2021 and 20-fold growth in innovations between 2022-2020, as proxied by patents. However, not all are poised to benefit from such developments, as big divides emerge.

Over 80% of high-impact neuroscience publications are produced by only ten countries, while 70% of countries contributed fewer than 10 such papers over the period considered. Similarly, five countries only hold 87% of IP5 neurotech patents.

This report sheds light on the neurotechnology ecosystem, that is, what is being developed, where and by whom, and informs about how neurotechnology interacts with other technological trajectories, especially Artificial Intelligence [emphasis mine]. [p. 2]

The money aspect is eye-opening even when you already have your suspicions. Also, it’s not entirely unexpected to learn that only ten countries produce over 80% of the high impact neurotech papers and that only five countries hold 87% of the IP5 neurotech patents but it is stunning to see it in context. (If you’re not familiar with the term ‘IP5 patents’, scroll down in this post to the relevant subhead. Hint: It means the patent was filed in one of the top five jurisdictions; I’ll leave you to guess which ones those might be.)

“Since 2013 …” isn’t quite as informative as the authors may have hoped. I wish they had given a time frame for government investments similar to what they did for corporate investments (e.g., 2010 – 2020). Also, is the $6B (likely in USD) government investment cumulative or an estimated annual number? To sum up, I would have appreciated parallel structure and specificity.

Nitpicks aside, there’s some very good material intended for policy makers. On that note, some of the analysis is beyond me. I haven’t used anything even somewhat close to their analytical tools in years and years. This commentaries reflects my interests and a very rapid reading. One last thing, this is being written from a Canadian perspective. With those caveats in mind, here’s some of what I found.

A definition, social issues, country statistics, and more

There’s a definition for neurotechnology and a second mention of artificial intelligence being used in concert with neurotechnology. From the report‘s executive summary,

Neurotechnology consists of devices and procedures used to access, monitor, investigate, assess, manipulate, and/or emulate the structure and function of the neural systems of animals or human beings. It is poised to revolutionize our understanding of the brain and to unlock innovative solutions to treat a wide range of diseases and disorders.

Similarly to Artificial Intelligence (AI), and also due to its convergence with AI, neurotechnology may have profound societal and economic impact, beyond the medical realm. As neurotechnology directly relates to the brain, it triggers ethical considerations about fundamental aspects of human existence, including mental integrity, human dignity, personal identity, freedom of thought, autonomy, and privacy [emphases mine]. Its potential for enhancement purposes and its accessibility further amplifies its prospect social and societal implications.

The recent discussions held at UNESCO’s Executive Board further shows Member States’ desire to address the ethics and governance of neurotechnology through the elaboration of a new standard-setting instrument on the ethics of neurotechnology, to be adopted in 2025. To this end, it is important to explore the neurotechnology landscape, delineate its boundaries, key players, and trends, and shed light on neurotech’s scientific and technological developments. [p. 7]

Here’s how they sourced the data for the report,

The present report addresses such a need for evidence in support of policy making in
relation to neurotechnology by devising and implementing a novel methodology on data from scientific articles and patents:

● We detect topics over time and extract relevant keywords using a transformer-
based language models fine-tuned for scientific text. Publication data for the period
2000-2021 are sourced from the Scopus database and encompass journal articles
and conference proceedings in English. The 2,000 most cited publications per year
are further used in in-depth content analysis.
● Keywords are identified through Named Entity Recognition and used to generate
search queries for conducting a semantic search on patents’ titles and abstracts,
using another language model developed for patent text. This allows us to identify
patents associated with the identified neuroscience publications and their topics.
The patent data used in the present analysis are sourced from the European
Patent Office’s Worldwide Patent Statistical Database (PATSTAT). We consider
IP5 patents filed between 2000-2020 having an English language abstract and
exclude patents solely related to pharmaceuticals.

This approach allows mapping the advancements detailed in scientific literature to the technological applications contained in patent applications, allowing for an analysis of the linkages between science and technology. This almost fully automated novel approach allows repeating the analysis as neurotechnology evolves. [pp. 8-9[

Findings in bullet points,

Key stylized facts are:
● The field of neuroscience has witnessed a remarkable surge in the overall number
of publications since 2000, exhibiting a nearly 35-fold increase over the period
considered, reaching 1.2 million in 2021. The annual number of publications in
neuroscience has nearly tripled since 2000, exceeding 90,000 publications a year
in 2021. This increase became even more pronounced since 2019.
● The United States leads in terms of neuroscience publication output (40%),
followed by the United Kingdom (9%), Germany (7%), China (5%), Canada (4%),
Japan (4%), Italy (4%), France (4%), the Netherlands (3%), and Australia (3%).
These countries account for over 80% of neuroscience publications from 2000 to
2021.
● Big divides emerge, with 70% of countries in the world having less than 10 high-
impact neuroscience publications between 2000 to 2021.
● Specific neurotechnology-related research trends between 2000 and 2021 include:
○ An increase in Brain-Computer Interface (BCI) research around 2010,
maintaining a consistent presence ever since.
○ A significant surge in Epilepsy Detection research in 2017 and 2018,
reflecting the increased use of AI and machine learning in healthcare.
○ Consistent interest in Neuroimaging Analysis, which peaks around 2004,
likely because of its importance in brain activity and language
comprehension studies.
○ While peaking in 2016 and 2017, Deep Brain Stimulation (DBS) remains a
persistent area of research, underlining its potential in treating conditions
like Parkinson’s disease and essential tremor.
● Between 2000 and 2020, the total number of patent applications in this field
increased significantly, experiencing a 20-fold increase from less than 500 to over
12,000. In terms of annual figures, a consistent upward trend in neurotechnology-10
related patent applications emerges, with a notable doubling observed between
2015 and 2020.
• The United States account for nearly half of all worldwide patent applications (47%).
Other major contributors include South Korea (11%), China (10%), Japan (7%),
Germany (7%), and France (5%). These five countries together account for 87%
of IP5 neurotech patents applied between 2000 and 2020.
○ The United States has historically led the field, with a peak around 2010, a
decline towards 2015, and a recovery up to 2020.
○ South Korea emerged as a significant contributor after 1990, overtaking
Germany in the late 2000s to become the second-largest developer of
neurotechnology. By the late 2010s, South Korea’s annual neurotechnology
patent applications approximated those of the United States.
○ China exhibits a sharp increase in neurotechnology patent applications in
the mid-2010s, bringing it on par with the United States in terms of
application numbers.
● The United States ranks highest in both scientific publications and patents,
indicating their strong ability to transform knowledge into marketable inventions.
China, France, and Korea excel in leveraging knowledge to develop patented
innovations. Conversely, countries such as the United Kingdom, Germany, Italy,
Canada, Brazil, and Australia lag behind in effectively translating neurotech
knowledge into patentable innovations.
● In terms of patent quality measured by forward citations, the leading countries are
Germany, US, China, Japan, and Korea.
● A breakdown of patents by technology field reveals that Computer Technology is
the most important field in neurotechnology, exceeding Medical Technology,
Biotechnology, and Pharmaceuticals. The growing importance of algorithmic
applications, including neural computing techniques, also emerges by looking at
the increase in patent applications in these fields between 2015-2020. Compared
to the reference year, computer technologies-related patents in neurotech
increased by 355% and by 92% in medical technology.
● An analysis of the specialization patterns of the top-5 countries developing
neurotechnologies reveals that Germany has been specializing in chemistry-
related technology fields, whereas Asian countries, particularly South Korea and
China, focus on computer science and electrical engineering-related fields. The
United States exhibits a balanced configuration with specializations in both
chemistry and computer science-related fields.
● The entities – i.e. both companies and other institutions – leading worldwide
innovation in the neurotech space are: IBM (126 IP5 patents, US), Ping An
Technology (105 IP5 patents, CH), Fujitsu (78 IP5 patents, JP), Microsoft (76 IP511
patents, US)1, Samsung (72 IP5 patents, KR), Sony (69 IP5 patents JP) and Intel
(64 IP5 patents US)

This report further proposes a pioneering taxonomy of neurotechnologies based on International Patent Classification (IPC) codes.

• 67 distinct patent clusters in neurotechnology are identified, which mirror the diverse research and development landscape of the field. The 20 most prominent neurotechnology groups, particularly in areas like multimodal neuromodulation, seizure prediction, neuromorphic computing [emphasis mine], and brain-computer interfaces, point to potential strategic areas for research and commercialization.
• The variety of patent clusters identified mirrors the breadth of neurotechnology’s potential applications, from medical imaging and limb rehabilitation to sleep optimization and assistive exoskeletons.
• The development of a baseline IPC-based taxonomy for neurotechnology offers a structured framework that enriches our understanding of this technological space, and can facilitate research, development and analysis. The identified key groups mirror the interdisciplinary nature of neurotechnology and underscores the potential impact of neurotechnology, not only in healthcare but also in areas like information technology and biomaterials, with non-negligible effects over societies and economies.

1 If we consider Microsoft Technology Licensing LLM and Microsoft Corporation as being under the same umbrella, Microsoft leads worldwide developments with 127 IP5 patents. Similarly, if we were to consider that Siemens AG and Siemens Healthcare GmbH belong to the same conglomerate, Siemens would appear much higher in the ranking, in third position, with 84 IP5 patents. The distribution of intellectual property assets across companies belonging to the same conglomerate is frequent and mirrors strategic as well as operational needs and features, among others. [pp. 9-11]

Surprises and comments

Interesting and helpful to learn that “neurotechnology interacts with other technological trajectories, especially Artificial Intelligence;” this has changed and improved my understanding of neurotechnology.

It was unexpected to find Canada in the top ten countries producing neuroscience papers. However, finding out that the country lags in translating its ‘neuro’ knowledge into patentable innovation is not entirely a surprise.

It can’t be an accident that countries with major ‘electronics and computing’ companies lead in patents. These companies do have researchers but they also buy startups to acquire patents. They (and ‘patent trolls’) will also file patents preemptively. For the patent trolls, it’s a moneymaking proposition and for the large companies, it’s a way of protecting their own interests and/or (I imagine) forcing a sale.

The mention of neuromorphic (brainlike) computing in the taxonomy section was surprising and puzzling. Up to this point, I’ve thought of neuromorphic computing as a kind of alternative or addition to standard computing but the authors have blurred the lines as per UNESCO’s definition of neurotechnology (specifically, “… emulate the structure and function of the neural systems of animals or human beings”) . Again, this report is broadening my understanding of neurotechnology. Of course, it required two instances before I quite grasped it, the definition and the taxonomy.

What’s puzzling is that neuromorphic engineering, a broader term that includes neuromorphic computing, isn’t used or mentioned. (For an explanation of the terms neuromorphic computing and neuromorphic engineering, there’s my June 23, 2023 posting, “Neuromorphic engineering: an overview.” )

The report

I won’t have time for everything. Here are some of the highlights from my admittedly personal perspective.

It’s not only about curing disease

From the report,

Neurotechnology’s applications however extend well beyond medicine [emphasis mine], and span from research, to education, to the workplace, and even people’s everyday life. Neurotechnology-based solutions may enhance learning and skill acquisition and boost focus through brain stimulation techniques. For instance, early research finds that brain- zapping caps appear to boost memory for at least one month (Berkeley, 2022). This could one day be used at home to enhance memory functions [emphasis mine]. They can further enable new ways to interact with the many digital devices we use in everyday life, transforming the way we work, live and interact. One example is the Sound Awareness wristband developed by a Stanford team (Neosensory, 2022) which enables individuals to “hear” by converting sound into tactile feedback, so that sound impaired individuals can perceive spoken words through their skin. Takagi and Nishimoto (2023) analyzed the brain scans taken through Magnetic Resonance Imaging (MRI) as individuals were shown thousands of images. They then trained a generative AI tool called Stable Diffusion2 on the brain scan data of the study’s participants, thus creating images that roughly corresponded to the real images shown. While this does not correspond to reading the mind of people, at least not yet, and some limitations of the study have been highlighted (Parshall, 2023), it nevertheless represents an important step towards developing the capability to interface human thoughts with computers [emphasis mine], via brain data interpretation.

While the above examples may sound somewhat like science fiction, the recent uptake of generative Artificial Intelligence applications and of large language models such as ChatGPT or Bard, demonstrates that the seemingly impossible can quickly become an everyday reality. At present, anyone can purchase online electroencephalogram (EEG) devices for a few hundred dollars [emphasis mine], to measure the electrical activity of their brain for meditation, gaming, or other purposes. [pp. 14-15]

This is very impressive achievement. Some of the research cited was published earlier this year (2023). The extraordinary speed is a testament to the efforts by the authors and their teams. It’s also a testament to how quickly the field is moving.

I’m glad to see the mention of and focus on consumer neurotechnology. (While the authors don’t speculate, I am free to do so.) Consumer neurotechnology could be viewed as one of the steps toward normalizing a cyborg future for all of us. Yes, we have books, television programmes, movies, and video games, which all normalize the idea but the people depicted have been severely injured and require the augmentation. With consumer neurotechnology, you have easily accessible devices being used to enhance people who aren’t injured, they just want to be ‘better’.

This phrase seemed particularly striking “… an important step towards developing the capability to interface human thoughts with computers” in light of some claims made by the Australian military in my June 13, 2023 posting “Mind-controlled robots based on graphene: an Australian research story.” (My posting has an embedded video demonstrating the Brain Robotic Interface (BRI) in action. Also, see the paragraph below the video for my ‘measured’ response.)

There’s no mention of the military in the report which seems more like a deliberate rather than inadvertent omission given the importance of military innovation where technology is concerned.

This section gives a good overview of government initiatives (in the report it’s followed by a table of the programmes),

Thanks to the promises it holds, neurotechnology has garnered significant attention from both governments and the private sector and is considered by many as an investment priority. According to the International Brain Initiative (IBI), brain research funding has become increasingly important over the past ten years, leading to a rise in large-scale state-led programs aimed at advancing brain intervention technologies(International Brain Initiative, 2021). Since 2013, initiatives such as the United States’ Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative and the European Union’s Human Brain Project (HBP), as well as major national initiatives in China, Japan and South Korea have been launched with significant funding support from the respective governments. The Canadian Brain Research Strategy, initially operated as a multi- stakeholder coalition on brain research, is also actively seeking funding support from the government to transform itself into a national research initiative (Canadian Brain Research Strategy, 2022). A similar proposal is also seen in the case of the Australian Brain Alliance, calling for the establishment of an Australian Brain Initiative (Australian Academy of Science, n.d.). [pp. 15-16]

Privacy

There are some concerns such as these,

Beyond the medical realm, research suggests that emotional responses of consumers
related to preferences and risks can be concurrently tracked by neurotechnology, such
as neuroimaging and that neural data can better predict market-level outcomes than
traditional behavioral data (Karmarkar and Yoon, 2016). As such, neural data is
increasingly sought after in the consumer market for purposes such as digital
phenotyping4, neurogaming 5,and neuromarketing6 (UNESCO, 2021). This surge in demand gives rise to risks like hacking, unauthorized data reuse, extraction of privacy-sensitive information, digital surveillance, criminal exploitation of data, and other forms of abuse. These risks prompt the question of whether neural data needs distinct definition and safeguarding measures.

These issues are particularly relevant today as a wide range of electroencephalogram (EEG) headsets that can be used at home are now available in consumer markets for purposes that range from meditation assistance to controlling electronic devices through the mind. Imagine an individual is using one of these devices to play a neurofeedback game, which records the person’s brain waves during the game. Without the person being aware, the system can also identify the patterns associated with an undiagnosed mental health condition, such as anxiety. If the game company sells this data to third parties, e.g. health insurance providers, this may lead to an increase of insurance fees based on undisclosed information. This hypothetical situation would represent a clear violation of mental privacy and of unethical use of neural data.

Another example is in the field of advertising, where companies are increasingly interested in using neuroimaging to better understand consumers’ responses to their products or advertisements, a practice known as neuromarketing. For instance, a company might use neural data to determine which advertisements elicit the most positive emotional responses in consumers. While this can help companies improve their marketing strategies, it raises significant concerns about mental privacy. Questions arise in relation to consumers being aware or not that their neural data is being used, and in the extent to which this can lead to manipulative advertising practices that unfairly exploit unconscious preferences. Such potential abuses underscore the need for explicit consent and rigorous data protection measures in the use of neurotechnology for neuromarketing purposes. [pp. 21-22]

Legalities

Some countries already have laws and regulations regarding neurotechnology data,

At the national level, only a few countries have enacted laws and regulations to protect mental integrity or have included neuro-data in personal data protection laws (UNESCO, University of Milan-Bicocca (Italy) and State University of New York – Downstate Health Sciences University, 2023). Examples are the constitutional reform undertaken by Chile (Republic of Chile, 2021), the Charter for the responsible development of neurotechnologies of the Government of France (Government of France, 2022), and the Digital Rights Charter of the Government of Spain (Government of Spain, 2021). They propose different approaches to the regulation and protection of human rights in relation to neurotechnology. Countries such as the UK are also examining under which circumstances neural data may be considered as a special category of data under the general data protection framework (i.e. UK’s GDPR) (UK’s Information Commissioner’s Office, 2023) [p. 24]

As you can see, these are recent laws. There doesn’t seem to be any attempt here in Canada even though there is an act being reviewed in Parliament that could conceivably include neural data. This is from my May 1, 2023 posting,

Bill C-27 (Digital Charter Implementation Act, 2022) is what I believe is called an omnibus bill as it includes three different pieces of proposed legislation (the Consumer Privacy Protection Act [CPPA], the Artificial Intelligence and Data Act [AIDA], and the Personal Information and Data Protection Tribunal Act [PIDPTA]). [emphasis added July 11, 2023] You can read the Innovation, Science and Economic Development (ISED) Canada summary here or a detailed series of descriptions of the act here on the ISED’s Canada’s Digital Charter webpage.

My focus at the time was artificial intelligence and, now, after reading this UNESCO report and briefly looking at the Innovation, Science and Economic Development (ISED) Canada summary and a detailed series of descriptions of the act on ISED’s Canada’s Digital Charter webpage, I don’t see anything that specifies neural data but it’s not excluded either.

IP5 patents

Here’s the explanation (the footnote is included at the end of the excerpt),

IP5 patents represent a subset of overall patents filed worldwide, which have the
characteristic of having been filed in at least one top intellectual property offices (IPO)
worldwide (the so called IP5, namely the Chinese National Intellectual Property
Administration, CNIPA (formerly SIPO); the European Patent Office, EPO; the Japan
Patent Office, JPO; the Korean Intellectual Property Office, KIPO; and the United States
Patent and Trademark Office, USPTO) as well as another country, which may or may not be an IP5. This signals their potential applicability worldwide, as their inventiveness and industrial viability have been validated by at least two leading IPOs. This gives these patents a sort of “quality” check, also since patenting inventions is costly and if applicants try to protect the same invention in several parts of the world, this normally mirrors that the applicant has expectations about their importance and expected value. If we were to conduct the same analysis using information about individually considered patent applied worldwide, i.e. without filtering for quality nor considering patent families, we would risk conducting a biased analysis based on duplicated data. Also, as patentability standards vary across countries and IPOs, and what matters for patentability is the existence (or not) of prior art in the IPO considered, we would risk mixing real innovations with patents related to catching up phenomena in countries that are not at the forefront of the technology considered.

9 The five IP offices (IP5) is a forum of the five largest intellectual property offices in the world that was set up to improve the efficiency of the examination process for patents worldwide. The IP5 Offices together handle about 80% of the world’s patent applications, and 95% of all work carried out under the Patent Cooperation Treaty (PCT), see http://www.fiveipoffices.org. (Dernis et al., 2015) [p. 31]

AI assistance on this report

As noted earlier I have next to no experience with the analytical tools having not attempted this kind of work in several years. Here’s an example of what they were doing,

We utilize a combination of text embeddings based on Bidirectional Encoder
Representations from Transformer (BERT), dimensionality reduction, and hierarchical
clustering inspired by the BERTopic methodology 12 to identify latent themes within
research literature. Latent themes or topics in the context of topic modeling represent
clusters of words that frequently appear together within a collection of documents (Blei, 2012). These groupings are not explicitly labeled but are inferred through computational analysis examining patterns in word usage. These themes are ‘hidden’ within the text, only to be revealed through this analysis. …

We further utilize OpenAI’s GPT-4 model to enrich our understanding of topics’ keywords and to generate topic labels (OpenAI, 2023), thus supplementing expert review of the broad interdisciplinary corpus. Recently, GPT-4 has shown impressive results in medical contexts across various evaluations (Nori et al., 2023), making it a useful tool to enhance the information obtained from prior analysis stages, and to complement them. The automated process enhances the evaluation workflow, effectively emphasizing neuroscience themes pertinent to potential neurotechnology patents. Notwithstanding existing concerns about hallucinations (Lee, Bubeck and Petro, 2023) and errors in generative AI models, this methodology employs the GPT-4 model for summarization and interpretation tasks, which significantly mitigates the likelihood of hallucinations. Since the model is constrained to the context provided by the keyword collections, it limits the potential for fabricating information outside of the specified boundaries, thereby enhancing the accuracy and reliability of the output. [pp. 33-34]

I couldn’t resist adding the ChatGPT paragraph given all of the recent hoopla about it.

Multimodal neuromodulation and neuromorphic computing patents

I think this gives a pretty good indication of the activity on the patent front,

The largest, coherent topic, termed “multimodal neuromodulation,” comprises 535
patents detailing methodologies for deep or superficial brain stimulation designed to
address neurological and psychiatric ailments. These patented technologies interact with various points in neural circuits to induce either Long-Term Potentiation (LTP) or Long-Term Depression (LTD), offering treatment for conditions such as obsession, compulsion, anxiety, depression, Parkinson’s disease, and other movement disorders. The modalities encompass implanted deep-brain stimulators (DBS), Transcranial Magnetic Stimulation (TMS), and transcranial Direct Current Stimulation (tDCS). Among the most representative documents for this cluster are patents with titles: Electrical stimulation of structures within the brain or Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson’s disease and or other movement disorders. [p.65]

Given my longstanding interest in memristors, which (I believe) have to a large extent helped to stimulate research into neuromorphic computing, this had to be included. Then, there was the brain-computer interfaces cluster,

A cluster identified as “Neuromorphic Computing” consists of 366 patents primarily
focused on devices designed to mimic human neural networks for efficient and adaptable computation. The principal elements of these inventions are resistive memory cells and artificial synapses. They exhibit properties similar to the neurons and synapses in biological brains, thus granting these devices the ability to learn and modulate responses based on rewards, akin to the adaptive cognitive capabilities of the human brain.

The primary technology classes associated with these patents fall under specific IPC
codes, representing the fields of neural network models, analog computers, and static
storage structures. Essentially, these classifications correspond to technologies that are key to the construction of computers and exhibit cognitive functions similar to human brain processes.

Examples for this cluster include neuromorphic processing devices that leverage
variations in resistance to store and process information, artificial synapses exhibiting
spike-timing dependent plasticity, and systems that allow event-driven learning and
reward modulation within neuromorphic computers.

In relation to neurotechnology as a whole, the “neuromorphic computing” cluster holds significant importance. It embodies the fusion of neuroscience and technology, thereby laying the basis for the development of adaptive and cognitive computational systems. Understanding this specific cluster provides a valuable insight into the progressing domain of neurotechnology, promising potential advancements across diverse fields, including artificial intelligence and healthcare.

The “Brain-Computer Interfaces” cluster, consisting of 146 patents, embodies a key aspect of neurotechnology that focuses on improving the interface between the brain and external devices. The technology classification codes associated with these patents primarily refer to methods or devices for treatment or protection of eyes and ears, devices for introducing media into, or onto, the body, and electric communication techniques, which are foundational elements of brain-computer interface (BCI) technologies.

Key patents within this cluster include a brain-computer interface apparatus adaptable to use environment and method of operating thereof, a double closed circuit brain-machine interface system, and an apparatus and method of brain-computer interface for device controlling based on brain signal. These inventions mainly revolve around the concept of using brain signals to control external devices, such as robotic arms, and improving the classification performance of these interfaces, even after long periods of non-use.

The inventions described in these patents improve the accuracy of device control, maintain performance over time, and accommodate multiple commands, thus significantly enhancing the functionality of BCIs.

Other identified technologies include systems for medical image analysis, limb rehabilitation, tinnitus treatment, sleep optimization, assistive exoskeletons, and advanced imaging techniques, among others. [pp. 66-67]

Having sections on neuromorphic computing and brain-computer interface patents in immediate proximity led to more speculation on my part. Imagine how much easier it would be to initiate a BCI connection if it’s powered with a neuromorphic (brainlike) computer/device. [ETA July 21, 2023: Following on from that thought, it might be more than just easier to initiate a BCI connection. Could a brainlike computer become part of your brain? Why not? it’s been successfully argued that a robotic wheelchair was part of someone’s body, see my January 30, 2013 posting and scroll down about 40% of the way.)]

Neurotech policy debates

The report concludes with this,

Neurotechnology is a complex and rapidly evolving technological paradigm whose
trajectories have the power to shape people’s identity, autonomy, privacy, sentiments,
behaviors and overall well-being, i.e. the very essence of what it means to be human.

Designing and implementing careful and effective norms and regulations ensuring that neurotechnology is developed and deployed in an ethical manner, for the good of
individuals and for society as a whole, call for a careful identification and characterization of the issues at stake. This entails shedding light on the whole neurotechnology ecosystem, that is what is being developed, where and by whom, and also understanding how neurotechnology interacts with other developments and technological trajectories, especially AI. Failing to do so may result in ineffective (at best) or distorted policies and policy decisions, which may harm human rights and human dignity.

Addressing the need for evidence in support of policy making, the present report offers first time robust data and analysis shedding light on the neurotechnology landscape worldwide. To this end, its proposes and implements an innovative approach that leverages artificial intelligence and deep learning on data from scientific publications and paten[t]s to identify scientific and technological developments in the neurotech space. The methodology proposed represents a scientific advance in itself, as it constitutes a quasi- automated replicable strategy for the detection and documentation of neurotechnology- related breakthroughs in science and innovation, to be repeated over time to account for the evolution of the sector. Leveraging this approach, the report further proposes an IPC-based taxonomy for neurotechnology which allows for a structured framework to the exploration of neurotechnology, to enable future research, development and analysis. The innovative methodology proposed is very flexible and can in fact be leveraged to investigate different emerging technologies, as they arise.

In terms of technological trajectories, we uncover a shift in the neurotechnology industry, with greater emphasis being put on computer and medical technologies in recent years, compared to traditionally dominant trajectories related to biotechnology and pharmaceuticals. This shift warrants close attention from policymakers, and calls for attention in relation to the latest (converging) developments in the field, especially AI and related methods and applications and neurotechnology.

This is all the more important and the observed growth and specialization patterns are unfolding in the context of regulatory environments that, generally, are either not existent or not fit for purpose. Given the sheer implications and impact of neurotechnology on the very essence of human beings, this lack of regulation poses key challenges related to the possible infringement of mental integrity, human dignity, personal identity, privacy, freedom of thought, and autonomy, among others. Furthermore, issues surrounding accessibility and the potential for neurotech enhancement applications triggers significant concerns, with far-reaching implications for individuals and societies. [pp. 72-73]

Last words about the report

Informative, readable, and thought-provoking. And, it helped broaden my understanding of neurotechnology.

Future endeavours?

I’m hopeful that one of these days one of these groups (UNESCO, Canadian Science Policy Centre, or ???) will tackle the issue of business bankruptcy in the neurotechnology sector. It has already occurred as noted in my ““Going blind when your neural implant company flirts with bankruptcy [long read]” April 5, 2022 posting. That story opens with a woman going blind in a New York subway when her neural implant fails. It’s how she found out the company, which supplied her implant was going out of business.

In my July 7, 2023 posting about the UNESCO July 2023 dialogue on neurotechnology, I’ve included information on Neuralink (one of Elon Musk’s companies) and its approval (despite some investigations) by the US Food and Drug Administration to start human clinical trials. Scroll down about 75% of the way to the “Food for thought” subhead where you will find stories about allegations made against Neuralink.

The end

If you want to know more about the field, the report offers a seven-page bibliography and there’s a lot of material here where you can start with this December 3, 2019 posting “Neural and technological inequalities” which features an article mentioning a discussion between two scientists. Surprisingly (to me), the source article is in Fast Company (a leading progressive business media brand), according to their tagline)..

I have two categories you may want to check: Human Enhancement and Neuromorphic Engineering. There are also a number of tags: neuromorphic computing, machine/flesh, brainlike computing, cyborgs, neural implants, neuroprosthetics, memristors, and more.

Should you have any observations or corrections, please feel free to leave them in the Comments section of this posting.

Global dialogue on the ethics of neurotechnology on July 13, 2023 led by UNESCO

While there’s a great deal of attention and hyperbole attached to artificial intelligence (AI) these days, it seems that neurotechnology may be quietly gaining much needed attention. (For those who are interested, at the end of this posting, there’ll be a bit more information to round out what you’re seeing in the UNESCO material.)

Now, here’s news of an upcoming UNESCO (United Nations Educational, Scientific, and Cultural Organization) meeting on neurotechnology, from a June 6, 2023 UNESCO press release (also received via email), Note: Links have been removed,

The Member States of the Executive Board of UNESCO
have approved the proposal of the Director General to hold a global
dialogue to develop an ethical framework for the growing and largely
unregulated Neurotechnology sector, which may threaten human rights and
fundamental freedoms. A first international conference will be held at
UNESCO Headquarters on 13 July 2023.

“Neurotechnology could help solve many health issues, but it could
also access and manipulate people’s brains, and produce information
about our identities, and our emotions. It could threaten our rights to
human dignity, freedom of thought and privacy. There is an urgent need
to establish a common ethical framework at the international level, as
UNESCO has done for artificial intelligence,” said UNESCO
Director-General Audrey Azoulay.

UNESCO’s international conference, taking place on 13 July [2023], will start
exploring the immense potential of neurotechnology to solve neurological
problems and mental disorders, while identifying the actions needed to
address the threats it poses to human rights and fundamental freedoms.
The dialogue will involve senior officials, policymakers, civil society
organizations, academics and representatives of the private sector from
all regions of the world.

Lay the foundations for a global ethical framework

The dialogue will also be informed by a report by UNESCO’s
International Bioethics Committee (IBC) on the “Ethical Issues of
Neurotechnology”, and a UNESCO study proposing first time evidence on
the neurotechnology landscape, innovations, key actors worldwide and
major trends.

The ultimate goal of the dialogue is to advance a better understanding
of the ethical issues related to the governance of neurotechnology,
informing the development of the ethical framework to be approved by 193
member states of UNESCO – similar to the way in which UNESCO
established the global ethical frameworks on the human genome (1997),
human genetic data (2003) and artificial intelligence (2021).

UNESCO’s global standard on the Ethics of Artificial Intelligence has
been particularly effective and timely, given the latest developments
related to Generative AI, the pervasiveness of AI technologies and the
risks they pose to people, democracies, and jobs. The convergence of
neural data and artificial intelligence poses particular challenges, as
already recognized in UNESCO’s AI standard.

Neurotech could reduce the burden of disease…

Neurotechnology covers any kind of device or procedure which is designed
to “access, monitor, investigate, assess, manipulate, and/or emulate
the structure and function of neural systems”. [1] Neurotechnological
devices range from “wearables”, to non-invasive brain computer
interfaces such as robotic limbs, to brain implants currently being
developed [2] with the goal of treating disabilities such as paralysis.

One in eight people worldwide live with a mental or neurological
disorder, triggering care-related costs that account for up to a third
of total health expenses in developed countries. These burdens are
growing in low- and middle-income countries too. Globally these expenses
are expected to grow – the number of people aged over 60 is projected
to double by 2050 to 2.1 billion (WHO 2022). Neurotechnology has the
vast potential to reduce the number of deaths and disabilities caused by
neurological disorders, such as Epilepsy, Alzheimer’s, Parkinson’s
and Stroke.

… but also threaten Human Rights

Without ethical guardrails, these technologies can pose serious risks, as
brain information can be accessed and manipulated, threatening
fundamental rights and fundamental freedoms, which are central to the
notion of human identity, freedom of thought, privacy, and memory. In
its report published in 2021 [3], UNESCO’s IBC documents these risks
and proposes concrete actions to address them.

Neural data – which capture the individual’s reactions and basic
emotions – is in high demand in consumer markets. Unlike the data
gathered on us by social media platforms, most neural data is generated
unconsciously, therefore we cannot give our consent for its use. If
sensitive data is extracted, and then falls into the wrong hands, the
individual may suffer harmful consequences.

Brain-Computer-Interfaces (BCIs) implanted at a time during which a
child or teenager is still undergoing neurodevelopment may disrupt the
‘normal’ maturation of the brain. It may be able to transform young
minds, shaping their future identity with long-lasting, perhaps
permanent, effects.

Memory modification techniques (MMT) may enable scientists to alter the
content of a memory, reconstructing past events. For now, MMT relies on
the use of drugs, but in the future it may be possible to insert chips
into the brain. While this could be beneficial in the case of
traumatised people, such practices can also distort an individual’s
sense of personal identity.

Risk of exacerbating global inequalities and generating new ones

Currently 50% of Neurotech Companies are in the US, and 35% in Europe
and the UK. Because neurotechnology could usher in a new generation of
‘super-humans’, this would further widen the education, skills, wealth
and opportunities’ gap within and between countries, giving those with
the most advanced technology an unfair advantage.

UNESCO’s Ethics of neurotechnology webpage can be found here. As for the July 13, 2023 dialogue/conference, here are some of the details from UNESCO’s International Conference on the Ethics of Neurotechnology webpage,

UNESCO will organize an International Conference on the Ethics of Neurotechnology on the theme “Building a framework to protect and promote human rights and fundamental freedoms” at UNESCO Headquarters in Paris, on 13 July 2023, from 9:00 [CET; Central European Time] in Room I.

The Conference will explore the immense potential of neurotechnology and address the ethical challenges it poses to human rights and fundamental freedoms. It will bring together policymakers and experts, representatives of civil society and UN organizations, academia, media, and private sector companies, to prepare a solid foundation for an ethical framework on the governance of neurotechnology.

UNESCO International Conference on Ethics of Neurotechnology: Building a framework to protect and promote human rights and fundamental freedoms
13 July 2023 – 9:30 am – 13 July 2023 – 6:30 pm [CET; Central European Time]
Location UNESCO Headquarters, Paris, France
Rooms : Room
I Type : Cat II – Intergovernmental meeting, other than international conference of States
Arrangement type : Hybrid
Language(s) : French Spanish English Arabic
Contact : Rajarajeswari Pajany

Registration

Click here to register

A high-level session with ministers and policy makers focusing on policy actions and international cooperation will be featured in the Conference. Renowned experts will also be invited to discuss technological advancements in Neurotechnology and ethical challenges and human rights Implications. Two fireside chats will be organized to enrich the discussions focusing on the private sector, public awareness raising and public engagement. The Conference will also feature a new study of UNESCO’s Social and Human Sciences Sector shedding light on innovations in neurotechnology, key actors worldwide and key areas of development.

As one of the most promising technologies of our time, neurotechnology is providing new treatments and improving preventative and therapeutic options for millions of individuals suffering from neurological and mental illness. Neurotechnology is also transforming other aspects of our lives, from student learning and cognition to virtual and augmented reality systems and entertainment. While we celebrate these unprecedented opportunities, we must be vigilant against new challenges arising from the rapid and unregulated development and deployment of this innovative technology, including among others the risks to mental integrity, human dignity, personal identity, autonomy, fairness and equity, and mental privacy. 

UNESCO has been at the forefront of promoting an ethical approach to neurotechnology. UNESCO’s International Bioethics Committee (IBC) has examined the benefits and drawbacks from an ethical perspective in a report published in December 2021. The Organization has also led UN-wide efforts on this topic, collaborating with other agencies and academic institutions to organize expert roundtables, raise public awareness and produce publications. With a global mandate on bioethics and ethics of science and technology, UNESCO has been asked by the IBC, its expert advisory body, to consider developing a global standard on this topic.

A July 13, 2023 agenda and a little Canadian content

I have a link to the ‘provisional programme‘ for “Towards an Ethical Framework in the Protection and Promotion of Human Rights and Fundamental Freedoms,” the July 13, 2023 UNESCO International Conference on Ethics of Neurotechnology. Keeping in mind that this could (and likely will) change,

13 July 2023, Room I,
UNESCO HQ Paris, France,

9:00 –9:15 Welcoming Remarks (TBC)
•António Guterres, Secretary-General of the United Nations•
•Audrey Azoulay, Director-General of UNESCO

9:15 –10:00 Keynote Addresses (TBC)
•Gabriel Boric, President of Chile
•Narendra Modi, Prime Minister of India
•PedroSánchez Pérez-Castejón, Prime Minister of Spain
•Volker Turk, UN High Commissioner for Human Rights
•Amandeep Singh Gill, UN Secretary-General’sEnvoyon Technology

10:15 –11:00 Scene-Setting Address

1:00 –13:00 High-Level Session: Regulations and policy actions

14:30 –15:30 Expert Session: Technological advancement and opportunities

15:45 –16:30 Fireside Chat: Launch of the UNESCO publication “Unveiling the neurotechnology landscape: scientific advancements, innovationsand major trends”

16:30 –17:30 Expert Session: Ethical challenges and human rights implications

17:30 –18:15 Fireside Chat: “Why neurotechnology matters for all

18:15 –18:30 Closing Remarks

While I haven’t included the speakers’ names (for the most part), I do want to note some Canadian participation in the person of Dr. Judy Iles from the University of British Columbia. She’s a Professor of Neurology, Distinguished University Scholar in Neuroethics, andDirector, Neuroethics Canada, and President of the International Brain Initiative (IBI)

Iles is in the “Expert Session: Ethical challenges and human rights implications.”

If you have time do look at the provisional programme just to get a sense of the range of speakers and their involvement in an astonishing array of organizations. E.g., there’s the IBI (in Judy Iles’s bio), which at this point is largely (and surprisingly) supported by (from About Us) “Fonds de recherche du Québec, and the Institute of Neuroscience, Mental Health and Addiction of the Canadian Institutes of Health Research. Operational support for the IBI is also provided by the Japan Brain/MINDS Beyond and WorldView Studios“.

More food for thought

Neither the UNESCO July 2023 meeting, which tilts, understandably, to social justice issues vis-à-vis neurotechnology nor the Canadian Science Policy Centre (CSPC) May 2023 meeting (see my May 12, 2023 posting: Virtual panel discussion: Canadian Strategies for Responsible Neurotechnology Innovation on May 16, 2023), based on the publicly available agendas, seem to mention practical matters such as an implant company going out of business. Still, it’s possible it will be mentioned at the UNESCO conference. Unfortunately, the May 2023 CSPC panel has not been posted online.

(See my April 5, 2022 posting “Going blind when your neural implant company flirts with bankruptcy [long read].” Even skimming it will give you some pause.) The 2019 OECD Recommendation on Responsible Innovation in Neurotechnology doesn’t cover/mention the issue ob business bankruptcy either.

Taking a look at business practices seems particularly urgent given this news from a May 25, 2023 article by Rachael Levy, Marisa Taylor, and Akriti Sharma for Reuters, Note: A link has been removed,

Elon Musk’s Neuralink received U.S. Food and Drug Administration (FDA) clearance for its first-in-human clinical trial, a critical milestone for the brain-implant startup as it faces U.S. probes over its handling of animal experiments.

The FDA approval “represents an important first step that will one day allow our technology to help many people,” Neuralink said in a tweet on Thursday, without disclosing details of the planned study. It added it is not recruiting for the trial yet and said more details would be available soon.

The FDA acknowledged in a statement that the agency cleared Neuralink to use its brain implant and surgical robot for trials on patients but declined to provide more details.

Neuralink and Musk did not respond to Reuters requests for comment.

The critical milestone comes as Neuralink faces federal scrutiny [emphasis mine] following Reuters reports about the company’s animal experiments.

Neuralink employees told Reuters last year that the company was rushing and botching surgeries on monkeys, pigs and sheep, resulting in more animal deaths [emphasis mine] than necessary, as Musk pressured staff to receive FDA approval. The animal experiments produced data intended to support the company’s application for human trials, the sources said.

If you have time, it’s well worth reading the article in its entirety. Neuralink is being investigated for a number of alleged violations.

Slightly more detail has been added by a May 26, 2023 Associated Press (AP article on the Canadian Broadcasting Corporation’s news online website,

Elon Musk’s brain implant company, Neuralink, says it’s gotten permission from U.S. regulators to begin testing its device in people.

The company made the announcement on Twitter Thursday evening but has provided no details about a potential study, which was not listed on the U.S. government database of clinical trials.

Officials with the Food and Drug Administration (FDA) wouldn’t confirm or deny whether it had granted the approval, but press officer Carly Kempler said in an email that the agency “acknowledges and understands” that Musk’s company made the announcement. [emphases mine]

The AP article offers additional context on the international race to develop brain-computer interfaces.

Update: It seems the FDA gave its approval later on May 26, 2023. (See the May 26, 2023 updated Reuters article by Rachael Levy, Marisa Taylor and Akriti Sharma and/or Paul Tuffley’s (lecturer at Griffith University) May 29, 2023 essay on The Conversation.)

For anyone who’s curious about previous efforts to examine ethics and social implications with regard to implants, prosthetics (Note: Increasingly, prosthetics include a neural component), and the brain, I have a couple of older posts: “Prosthetics and the human brain,” a March 8, 2013 and “The ultimate DIY: ‘How to build a robotic man’ on BBC 4,” a January 30, 2013 posting.)

Turning brain-controlled wireless electronic prostheses into reality plus some ethical points

Researchers at Stanford University (California, US) believe they have a solution for a problem with neuroprosthetics (Note: I have included brief comments about neuroprosthetics and possible ethical issues at the end of this posting) according an August 5, 2020 news item on ScienceDaily,

The current generation of neural implants record enormous amounts of neural activity, then transmit these brain signals through wires to a computer. But, so far, when researchers have tried to create wireless brain-computer interfaces to do this, it took so much power to transmit the data that the implants generated too much heat to be safe for the patient. A new study suggests how to solve his problem — and thus cut the wires.

Caption: Photo of a current neural implant, that uses wires to transmit information and receive power. New research suggests how to one day cut the wires. Credit: Sergey Stavisky

An August 3, 2020 Stanford University news release (also on EurekAlert but published August 4, 2020) by Tom Abate, which originated the news item, details the problem and the proposed solution,

Stanford researchers have been working for years to advance a technology that could one day help people with paralysis regain use of their limbs, and enable amputees to use their thoughts to control prostheses and interact with computers.

The team has been focusing on improving a brain-computer interface, a device implanted beneath the skull on the surface of a patient’s brain. This implant connects the human nervous system to an electronic device that might, for instance, help restore some motor control to a person with a spinal cord injury, or someone with a neurological condition like amyotrophic lateral sclerosis, also called Lou Gehrig’s disease.

The current generation of these devices record enormous amounts of neural activity, then transmit these brain signals through wires to a computer. But when researchers have tried to create wireless brain-computer interfaces to do this, it took so much power to transmit the data that the devices would generate too much heat to be safe for the patient.

Now, a team led by electrical engineers and neuroscientists Krishna Shenoy, PhD, and Boris Murmann, PhD, and neurosurgeon and neuroscientist Jaimie Henderson, MD, have shown how it would be possible to create a wireless device, capable of gathering and transmitting accurate neural signals, but using a tenth of the power required by current wire-enabled systems. These wireless devices would look more natural than the wired models and give patients freer range of motion.

Graduate student Nir Even-Chen and postdoctoral fellow Dante Muratore, PhD, describe the team’s approach in a Nature Biomedical Engineering paper.

The team’s neuroscientists identified the specific neural signals needed to control a prosthetic device, such as a robotic arm or a computer cursor. The team’s electrical engineers then designed the circuitry that would enable a future, wireless brain-computer interface to process and transmit these these carefully identified and isolated signals, using less power and thus making it safe to implant the device on the surface of the brain.

To test their idea, the researchers collected neuronal data from three nonhuman primates and one human participant in a (BrainGate) clinical trial.

As the subjects performed movement tasks, such as positioning a cursor on a computer screen, the researchers took measurements. The findings validated their hypothesis that a wireless interface could accurately control an individual’s motion by recording a subset of action-specific brain signals, rather than acting like the wired device and collecting brain signals in bulk.

The next step will be to build an implant based on this new approach and proceed through a series of tests toward the ultimate goal.

Here’s a link to and a citation for the paper,

Power-saving design opportunities for wireless intracortical brain–computer interfaces by Nir Even-Chen, Dante G. Muratore, Sergey D. Stavisky, Leigh R. Hochberg, Jaimie M. Henderson, Boris Murmann & Krishna V. Shenoy. Nature Biomedical Engineering (2020) DOI: https://doi.org/10.1038/s41551-020-0595-9 Published: 03 August 2020

This paper is behind a paywall.

Comments about ethical issues

As I found out while investigating, ethical issues in this area abound. My first thought was to look at how someone with a focus on ability studies might view the complexities.

My ‘go to’ resource for human enhancement and ethical issues is Gregor Wolbring, an associate professor at the University of Calgary (Alberta, Canada). his profile lists these areas of interest: ability studies, disability studies, governance of emerging and existing sciences and technologies (e.g. neuromorphic engineering, genetics, synthetic biology, robotics, artificial intelligence, automatization, brain machine interfaces, sensors) and more.

I can’t find anything more recent on this particular topic but I did find an August 10, 2017 essay for The Conversation where he comments on technology and human enhancement ethical issues where the technology is gene-editing. Regardless, he makes points that are applicable to brain-computer interfaces (human enhancement), Note: Links have been removed),

Ability expectations have been and still are used to disable, or disempower, many people, not only people seen as impaired. They’ve been used to disable or marginalize women (men making the argument that rationality is an important ability and women don’t have it). They also have been used to disable and disempower certain ethnic groups (one ethnic group argues they’re smarter than another ethnic group) and others.

A recent Pew Research survey on human enhancement revealed that an increase in the ability to be productive at work was seen as a positive. What does such ability expectation mean for the “us” in an era of scientific advancements in gene-editing, human enhancement and robotics?

Which abilities are seen as more important than others?

The ability expectations among “us” will determine how gene-editing and other scientific advances will be used.

And so how we govern ability expectations, and who influences that governance, will shape the future. Therefore, it’s essential that ability governance and ability literacy play a major role in shaping all advancements in science and technology.

One of the reasons I find Gregor’s commentary so valuable is that he writes lucidly about ability and disability as concepts and poses what can be provocative questions about expectations and what it is to be truly abled or disabled. You can find more of his writing here on his eponymous (more or less) blog.

Ethics of clinical trials for testing brain implants

This October 31, 2017 article by Emily Underwood for Science was revelatory,

In 2003, neurologist Helen Mayberg of Emory University in Atlanta began to test a bold, experimental treatment for people with severe depression, which involved implanting metal electrodes deep in the brain in a region called area 25 [emphases mine]. The initial data were promising; eventually, they convinced a device company, St. Jude Medical in Saint Paul, to sponsor a 200-person clinical trial dubbed BROADEN.

This month [October 2017], however, Lancet Psychiatry reported the first published data on the trial’s failure. The study stopped recruiting participants in 2012, after a 6-month study in 90 people failed to show statistically significant improvements between those receiving active stimulation and a control group, in which the device was implanted but switched off.

… a tricky dilemma for companies and research teams involved in deep brain stimulation (DBS) research: If trial participants want to keep their implants [emphases mine], who will take responsibility—and pay—for their ongoing care? And participants in last week’s meeting said it underscores the need for the growing corps of DBS researchers to think long-term about their planned studies.

… participants bear financial responsibility for maintaining the device should they choose to keep it, and for any additional surgeries that might be needed in the future, Mayberg says. “The big issue becomes cost [emphasis mine],” she says. “We transition from having grants and device donations” covering costs, to patients being responsible. And although the participants agreed to those conditions before enrolling in the trial, Mayberg says she considers it a “moral responsibility” to advocate for lower costs for her patients, even it if means “begging for charity payments” from hospitals. And she worries about what will happen to trial participants if she is no longer around to advocate for them. “What happens if I retire, or get hit by a bus?” she asks.

There’s another uncomfortable possibility: that the hypothesis was wrong [emphases mine] to begin with. A large body of evidence from many different labs supports the idea that area 25 is “key to successful antidepressant response,” Mayberg says. But “it may be too simple-minded” to think that zapping a single brain node and its connections can effectively treat a disease as complex as depression, Krakauer [John Krakauer, a neuroscientist at Johns Hopkins University in Baltimore, Maryland] says. Figuring that out will likely require more preclinical research in people—a daunting prospect that raises additional ethical dilemmas, Krakauer says. “The hardest thing about being a clinical researcher,” he says, “is knowing when to jump.”

Brain-computer interfaces, symbiosis, and ethical issues

This was the most recent and most directly applicable work that I could find. From a July 24, 2019 article by Liam Drew for Nature Outlook: The brain,

“It becomes part of you,” Patient 6 said, describing the technology that enabled her, after 45 years of severe epilepsy, to halt her disabling seizures. Electrodes had been implanted on the surface of her brain that would send a signal to a hand-held device when they detected signs of impending epileptic activity. On hearing a warning from the device, Patient 6 knew to take a dose of medication to halt the coming seizure.

“You grow gradually into it and get used to it, so it then becomes a part of every day,” she told Frederic Gilbert, an ethicist who studies brain–computer interfaces (BCIs) at the University of Tasmania in Hobart, Australia. “It became me,” she said. [emphasis mine]

Gilbert was interviewing six people who had participated in the first clinical trial of a predictive BCI to help understand how living with a computer that monitors brain activity directly affects individuals psychologically1. Patient 6’s experience was extreme: Gilbert describes her relationship with her BCI as a “radical symbiosis”.

Symbiosis is a term, borrowed from ecology, that means an intimate co-existence of two species for mutual advantage. As technologists work towards directly connecting the human brain to computers, it is increasingly being used to describe humans’ potential relationship with artificial intelligence.

Interface technologies are divided into those that ‘read’ the brain to record brain activity and decode its meaning, and those that ‘write’ to the brain to manipulate activity in specific regions and affect their function.

Commercial research is opaque, but scientists at social-media platform Facebook are known to be pursuing brain-reading techniques for use in headsets that would convert users’ brain activity into text. And neurotechnology companies such as Kernel in Los Angeles, California, and Neuralink, founded by Elon Musk in San Francisco, California, predict bidirectional coupling in which computers respond to people’s brain activity and insert information into their neural circuitry. [emphasis mine]

Already, it is clear that melding digital technologies with human brains can have provocative effects, not least on people’s agency — their ability to act freely and according to their own choices. Although neuroethicists’ priority is to optimize medical practice, their observations also shape the debate about the development of commercial neurotechnologies.

Neuroethicists began to note the complex nature of the therapy’s side effects. “Some effects that might be described as personality changes are more problematic than others,” says Maslen [Hannah Maslen, a neuroethicist at the University of Oxford, UK]. A crucial question is whether the person who is undergoing stimulation can reflect on how they have changed. Gilbert, for instance, describes a DBS patient who started to gamble compulsively, blowing his family’s savings and seeming not to care. He could only understand how problematic his behaviour was when the stimulation was turned off.

Such cases present serious questions about how the technology might affect a person’s ability to give consent to be treated, or for treatment to continue. [emphases mine] If the person who is undergoing DBS is happy to continue, should a concerned family member or doctor be able to overrule them? If someone other than the patient can terminate treatment against the patient’s wishes, it implies that the technology degrades people’s ability to make decisions for themselves. It suggests that if a person thinks in a certain way only when an electrical current alters their brain activity, then those thoughts do not reflect an authentic self.

To observe a person with tetraplegia bringing a drink to their mouth using a BCI-controlled robotic arm is spectacular. [emphasis mine] This rapidly advancing technology works by implanting an array of electrodes either on or in a person’s motor cortex — a brain region involved in planning and executing movements. The activity of the brain is recorded while the individual engages in cognitive tasks, such as imagining that they are moving their hand, and these recordings are used to command the robotic limb.

If neuroscientists could unambiguously discern a person’s intentions from the chattering electrical activity that they record in the brain, and then see that it matched the robotic arm’s actions, ethical concerns would be minimized. But this is not the case. The neural correlates of psychological phenomena are inexact and poorly understood, which means that signals from the brain are increasingly being processed by artificial intelligence (AI) software before reaching prostheses.[emphasis mine]

But, he [Philipp Kellmeyer, a neurologist and neuroethicist at the University of Freiburg, Germany] says, using AI tools also introduces ethical issues of which regulators have little experience. [emphasis mine] Machine-learning software learns to analyse data by generating algorithms that cannot be predicted and that are difficult, or impossible, to comprehend. This introduces an unknown and perhaps unaccountable process between a person’s thoughts and the technology that is acting on their behalf.

Maslen is already helping to shape BCI-device regulation. She is in discussion with the European Commission about regulations it will implement in 2020 that cover non-invasive brain-modulating devices that are sold straight to consumers. [emphases mine; Note: There is a Canadian company selling this type of product, MUSE] Maslen became interested in the safety of these devices, which were covered by only cursory safety regulations. Although such devices are simple, they pass electrical currents through people’s scalps to modulate brain activity. Maslen found reports of them causing burns, headaches and visual disturbances. She also says clinical studies have shown that, although non-invasive electrical stimulation of the brain can enhance certain cognitive abilities, this can come at the cost of deficits in other aspects of cognition.

Regarding my note about MUSE, the company is InteraXon and its product is MUSE.They advertise the product as “Brain Sensing Headbands That Improve Your Meditation Practice.” The company website and the product seem to be one entity, Choose Muse. The company’s product has been used in some serious research papers they can be found here. I did not see any research papers concerning safety issues.

Getting back to Drew’s July 24, 2019 article and Patient 6,

… He [Gilbert] is now preparing a follow-up report on Patient 6. The company that implanted the device in her brain to help free her from seizures went bankrupt. The device had to be removed.

… Patient 6 cried as she told Gilbert about losing the device. … “I lost myself,” she said.

“It was more than a device,” Gilbert says. “The company owned the existence of this new person.”

I strongly recommend reading Drew’s July 24, 2019 article in its entirety.

Finally

It’s easy to forget that in all the excitement over technologies ‘making our lives better’ that there can be a dark side or two. Some of the points brought forth in the articles by Wolbring, Underwood, and Drew confirmed my uneasiness as reasonable and gave me some specific examples of how these technologies raise new issues or old issues in new ways.

What I find interesting is that no one is using the term ‘cyborg’, which would seem quite applicable.There is an April 20, 2012 posting here titled ‘My mother is a cyborg‘ where I noted that by at lease one definition people with joint replacements, pacemakers, etc. are considered cyborgs. In short, cyborgs or technology integrated into bodies have been amongst us for quite some time.

Interestingly, no one seems to care much when insects are turned into cyborgs (can’t remember who pointed this out) but it is a popular area of research especially for military applications and search and rescue applications.

I’ve sometimes used the term ‘machine/flesh’ and or ‘augmentation’ as a description of technologies integrated with bodies, human or otherwise. You can find lots on the topic here however I’ve tagged or categorized it.

Amongst other pieces you can find here, there’s the August 8, 2016 posting, ‘Technology, athletics, and the ‘new’ human‘ featuring Oscar Pistorius when he was still best known as the ‘blade runner’ and a remarkably successful paralympic athlete. It’s about his efforts to compete against able-bodied athletes at the London Olympic Games in 2012. It is fascinating to read about technology and elite athletes of any kind as they are often the first to try out ‘enhancements’.

Gregor Wolbring has a number of essays on The Conversation looking at Paralympic athletes and their pursuit of enhancements and how all of this is affecting our notions of abilities and disabilities. By extension, one has to assume that ‘abled’ athletes are also affected with the trickle-down effect on the rest of us.

Regardless of where we start the investigation, there is a sameness to the participants in neuroethics discussions with a few experts and commercial interests deciding on how the rest of us (however you define ‘us’ as per Gregor Wolbring’s essay) will live.

This paucity of perspectives is something I was getting at in my COVID-19 editorial for the Canadian Science Policy Centre. My thesis being that we need a range of ideas and insights that cannot be culled from small groups of people who’ve trained and read the same materials or entrepreneurs who too often seem to put profit over thoughtful implementations of new technologies. (See the PDF May 2020 edition [you’ll find me under Policy Development]) or see my May 15, 2020 posting here (with all the sources listed.)

As for this new research at Stanford, it’s exciting news, which raises questions, as it offers the hope of independent movement for people diagnosed as tetraplegic (sometimes known as quadriplegic.)